[go: up one dir, main page]

WO2011146674A2 - Traitement de maladies liées à la protéine 11 de type bcl2 (bcl2l11) par inhibition de transcrits anti-sens naturels de bcl2l11 - Google Patents

Traitement de maladies liées à la protéine 11 de type bcl2 (bcl2l11) par inhibition de transcrits anti-sens naturels de bcl2l11 Download PDF

Info

Publication number
WO2011146674A2
WO2011146674A2 PCT/US2011/037079 US2011037079W WO2011146674A2 WO 2011146674 A2 WO2011146674 A2 WO 2011146674A2 US 2011037079 W US2011037079 W US 2011037079W WO 2011146674 A2 WO2011146674 A2 WO 2011146674A2
Authority
WO
WIPO (PCT)
Prior art keywords
oligonucleotide
antisense
polynucleotide
bcl2
bcl2l1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/037079
Other languages
English (en)
Other versions
WO2011146674A3 (fr
Inventor
Joseph Collard
Olga Khorkova Sherman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opko Curna LLC
Original Assignee
Opko Curna LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Curna LLC filed Critical Opko Curna LLC
Publication of WO2011146674A2 publication Critical patent/WO2011146674A2/fr
Publication of WO2011146674A3 publication Critical patent/WO2011146674A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Definitions

  • Embodiments of the invention comprise oligonucleotides modulating expression and/or function of BCL2L1 1 and associated molecules.
  • DNA-RNA and RNA-RNA hybridization arc important to many aspects of nucleic acid function including DNA replication, transcription, and translation. Hybridization is also central to a variety of technologies that either detect a particular nucleic acid or alter its expression. Antisensc nucleotides, for example, disrupt gene expression by hybridizing to target RNA, thereby interfering with RNA splicing, transcription, translation, and replication. Antisense DNA has the added feature that DNA-RNA hybrids serve as a substrate for digestion by ribonuclease H, an activity that is present in most cell types.
  • Antisense molecules can be delivered into cells, as is the case for oligodeoxynucleotides (ODNs), or they can be expressed from endogenous genes as RNA molecules.
  • ODNs oligodeoxynucleotides
  • VITRAVENETM for treatment of cytomegalovirus retinitis
  • the invention provides methods for inhibiting the action of a natural antisense transcript by using antisense oligonuclcotide(s) targeted to any region of the natural antisense transcript resulting in up-regulation of the corresponding sense gene. It is also contemplated herein that inhibition of the natural antisensc transcript can be achieved by siRNA, ribozymcs and small molecules, which are considered to be within the scope of the present invention.
  • One embodiment provides a method of modulating function and/or expression of an BCL2L1 1 polynucleotide in patient cells or tissues in vivo or in vitro comprising contacting said cells or tissues with an antisensc oligonucleotide 5 to 30 nucleotides in length wherein said oligonucleotide has at least 50% sequence identity to a reverse complement of a polynucleotide comprising 5 to 30 consecutive nucleotides within nucleotides I to 3026 of SEQ ID NO: 2 and I to 1512 of SEQ ID NO: 3 thereby modulating function and/or expression of the BCL2L1 1 polynucleotide in patient cells or tissues in vivo or in vitro.
  • an oligonucleotide targets a natural antisense sequence of BCL2L1 1 polynucleotides, for example, nucleotides set forth in SEQ ID NOS: 2 and 3, and any variants, alleles, homologs, mutants, derivatives, fragments and complementary sequences thereto.
  • antisense oligonucleotides arc set forth as SEQ ID NOS: 4 to 13.
  • Another embodiment provides a method of modulating function and/or expression of an BCL2L1 1 polynucleotide in patient cells or tissues in vivo or in vitro comprising contacting said cells or tissues with an antisense oligonucleotide 5 to 30 nucleotides in length wherein said oligonucleotide has at least 50% sequence identity to a reverse complement of the an antisense of the BCL2L1 1 polynucleotide; thereby modulating function and/or expression of the BCL2LI 1 polynucleotide in patient cells or tissues in vivo or in vitro.
  • Another embodiment provides a method of modulating function and/or expression of an BCL2LI I polynucleotide in patient cells or tissues in vivo or in vitro comprising contacting said cells or tissues with an antisense oligonucleotide 5 to 30 nucleotides in length wherein said oligonucleotide has at least 50% sequence identity to an antisense oligonucleotide to an BCL2LI 1 antisense polynucleotide; thereby modulating function and/or expression of the BCL2L 1 1 polynucleotide in patient cells or tissues in vivo or in vitro.
  • a composition comprises one or more antisense oligonucleotides which bind to sense and/or antisense BCL2L1 1 polynucleotides.
  • the oligonucleotides comprise one or more modified or substituted nucleotides.
  • the oligonucleotides comprise one or more modified bonds.
  • the modified nucleotides comprise modified bases comprising phosphorothioatc, mcthylphosphonatc, peptide nucleic acids, 2'-0-mcthyl, iluoro- or carbon, methylene or other locked nucleic acid (LNA) molecules.
  • the modified nucleotides are locked nucleic acid molecules, including a-L-LNA.
  • the oligonucleotides arc administered to a patient subcutaneously, intramuscularly, intravenously or intrapcritoncally.
  • the oligonucleotides are administered in a pharmaceutical composition.
  • a treatment regimen comprises administering the antisense compounds at least once to patient; however, this treatment can be modified to include multiple doses over a period of time.
  • the treatment can be combined with one or more other types of therapies.
  • the oligonucleotides arc encapsulated in a liposome or attached to a carrier molecule (e.g. cholesterol, TAT peptide).
  • a carrier molecule e.g. cholesterol, TAT peptide
  • Figure 1 is a graph of real time PCR results showing the fold change + standard deviation in BCL2L 1 1 mRN A after treatment of HepG2 cells with phosphorothioatc oligonucleotides introduced using Lipofectaminc 2000, as compared to control.
  • Real time PCR results show that the levels of the BIM mRNA in MCF-7 cells arc significantly increased 48 h after treatment with two of the oligos designed to BIM antisense Hs.652337. Bars denoted as CUR- 1521 and CUR- 1522 correspond to samples treated with SEQ ID NOS: 10 and 1 1 respectively.
  • FIG. 1 is a graph of real time PCR results showing the fold change + standard deviation in BCL2L 1 1 mRNA after treatment of HcpG2 cells with phosphorothioatc oligonucleotides introduced using Lipofcctaniine 2000, as compared to control.
  • Real time PCR results show that the levels of the BIM mRNA in HcpG2 cells arc significantly increased 48 h after treatment with one of the oligos designed to BIM antisense Hs.652337.
  • CUR- 1519, CUR- 1520, CUR- 1523, CUR- 1525, CUR- 1524, CUR- 1526, CUR- 1521 and CUR- 1522 correspond to samples treated with SEQ ID NOS: 4 to 13 respectively.
  • FIG. 3 shows fold change in BCL2L1 1 mRNA expression in primary keratinocytes treated with phosphorothioatc oligonucleotides.
  • CUR- 1.522 significantly uprcgulatcd BIM mRNA in Keratinocytes LL.
  • Bar denoted as CUR- 1522 correspond to sample treated with SEQ ID NO: 1 1.
  • FIG. 4 is a graph of Apoptosis Assay Results showing percent increase in Apoptosis in A549 cells treated with phophorothioate oligonucleotides introduced using lipofectamine 2000 as compared to control. Apoptosis results show that CUR- significantly increased apoptosis in A549 cells compared to control. Bars denoted as CUR-1 174 and CUR-1522 correspond to samples treated with SEQ ID NO: 1 1 and 12
  • FIG. 15 shows percent increase in Apoptosis in cells treated with phophorothioate oligonucleotides.
  • CUR- 1522 significantly increased apoptosis in cells compared to control.
  • Bars denoted as CUR- 151 , CUR-1521 CUR-1 522 and CUR- 1505 correspond to samples treated with SEQ ID NO: SEQ ID NO: 4, 10, 1 1 and 13
  • FIG. 6 shows percent increase in Apoptosis in cells treated with phophorothioate oligonucleotides.
  • CUR- 1522 significantly increased apoptosis in cells compared to control.
  • Bar denoted as CUR- 1519, CUR- 1521 CUR-1522 and CUR- 1505 correspond to samples treated with SEQ ID NO: 4, 10, 1 1 and 13
  • SEQ ID NO: 1 Homo sapiens BCL2-like 1 1 (apoptosis facilitator) (BCL2L1 1 ), transcript variant 9, mRNA (NCBI Accession No.: NM_2()7002); SEQ ID NO: 2: Natural BCL2L 1 1 antisense sequence (Hs.652337); SEQ ID NO: 3: Natural BCL2L1 1 antisense sequence (Hs.6 l 8461 ); SEQ ID NOs: 4 to 13: Antisense oligonucleotides. * indicates phosphothioate bond.
  • genes, gene names, and gene products disclosed herein arc intended to correspond to homologs from any species for which the compositions and methods disclosed herein are applicable.
  • the terms include, but arc not limited to genes and gene products from humans and mice. It is understood that when a gene or gene product from a particular species is disclosed, this disclosure is intended to be exemplary only, and is not to be interpreted as a limitation unless the context in which it appears clearly indicates.
  • the genes disclosed herein which in some embodiments relate to mammalian nucleic acid and amino acid sequences are intended to encompass homologous and/or orthologous genes and gene products from other animals including, but not limited to other mammals, fish, amphibians, reptiles, and birds.
  • the genes or nucleic acid sequences are human. Definitions
  • the term “about” or “approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 1 or more than I standard deviation, per the practice in the art. Alternatively, “about” can mean a range of up to 20%, preferably up to 10%, more preferably up to 5%, and more preferably still up to 1 % of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold, of a value. Where particular values are described in the application and claims, unless otherwise stated the term "about” meaning within an acceptable error range for the particular value should be assumed.
  • mRNA means the presently known mRNA transcript(s) of a targeted gene, and any further transcripts which may be elucidated.
  • antisense oligonucleotides or “antisense compound” is meant an RNA or DNA molecule that binds to anotlicr RNA or DNA (target RNA, DNA). For example, if it is an RNA oligonucleotide it binds to another RNA target by means of RNA-RNA interactions and alters the activity of the target RNA.
  • An antisense oligonucleotide can Liprcgulatc or downrcgulatc expression and/or function of a particular polynucleotide. The definition is meant to include any foreign RNA or DNA molecule which is useful from a therapeutic, diagnostic, or other viewpoint.
  • Such molecules include, for example, antisense RNA or DNA molecules, interference RNA (RNAi), micro RNA, decoy RNA molecules, siRNA, enzymatic RNA, therapeutic editing RNA and agonist and antagonist RNA, antisense oligomeric compounds, antiscnsc oligonucleotides, external guide sequence (EGS) oligonucleotides, alternate splicers, primers, probes, and other oligomcric compounds that hybridize to at least a portion of the target nucleic acid.
  • RNAi interference RNA
  • micro RNA decoy RNA molecules
  • siRNA siRNA
  • enzymatic RNA therapeutic editing RNA and agonist and antagonist RNA
  • antisense oligomeric compounds antiscnsc oligonucleotides
  • EGS external guide sequence oligonucleotides
  • alternate splicers primers, probes, and other oligomcric compounds that hybridize to at least a portion of the target nucleic
  • oligonucleotide refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimctics thereof.
  • oligonucleotide also includes linear or circular oligomers of natural and/or modified monomers or linkages, including deoxyribonucleosides, ribonucleosides, substituted and alpha-anomcric forms thereof, peptide nucleic acids (PNA), locked nucleic acids (LNA), phosphorothioatc, mcthylphosphonatc, and the like.
  • Oligonucleotides arc capable of specifically binding to a target polynucleotide by way of a regular pattern of monomer-to-monomer interactions, such as Watson-Crick type of base pairing, Hoogstccn or reverse Hoogstccn types of base pairing, or the like.
  • the oligonucleotide may be "chimeric", that is, composed of different regions.
  • "chimeric" compounds are oligonucleotides, which contain two or more chemical regions, for example, DNA region(s), RNA region(s), PNA region(s) etc. Each chemical region is made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotides compound.
  • These oligonucleotides typically comprise at least one region wherein the oligonucleotide is modified in order to exhibit one or more desired properties.
  • the desired properties of the oligonucleotide include, but are not limited, for example, to increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. Different regions of the oligonucleotide may therefore have different properties.
  • the chimeric oligonucleotides of die present invention can be formed as mixed structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide analogs as described above.
  • the oligonucleotide can be composed of regions that can be linked in "register", that is, when the monomers are linked consecutively, as in native DNA, or linked via spacers.
  • the spacers are intended to constitute a covalent "bridge” between the regions and have in preferred cases a length not exceeding about l(K) carbon atoms.
  • the spacers may carry different functionalities, for example, having positive or negative charge, carry special nucleic acid binding properties (intercalators, groove binders, toxins, fluorophors etc.), being lipophilic, inducing special secondary structures like, for example, alanine containing peptides that induce alpha-helices.
  • BCL2LI 1 and BCL2-likc 1 1 arc inclusive of all family members, mutants, alleles, fragments, species, coding and noncoding sequences, sense and antisense polynucleotide strands, etc.
  • BCL2-likc 1 1 , BCL2L1 1, BAM, Bcl2-intcracting mediator of cell death, Bcl2-L-1 1 , BIM, BIM-alpha6, BIM-beta6, BIM-beta7, BimEL, BitnL, BOD, are considered the same in the literature and are used interchangeably in the present application.
  • oligonucleotide specific for or "oligonucleotide which targets” refers to an oligonucleotide having a sequence (i) capable of forming a stable complex with a portion of the targeted gene, or (ii) capable of forming a stable duplex with a portion of a mRNA transcript of the targeted gene. Stability of the complexes and duplexes can be determined by theoretical calculations and/or in vitro assays. Exemplary assays for determining stabi lity of hybridization complexes and duplexes arc described in the Examples below.
  • target nucleic acid encompasses D A, RNA (comprising prcmR A and mRNA) transcribed from such DNA, and also cDNA derived from such RNA, coding, noncoding sequences, sense or antisense polynucleotides.
  • RNA comprising prcmR A and mRNA
  • cDNA derived from such RNA, coding, noncoding sequences, sense or antisense polynucleotides.
  • antisense The functions of DNA to be interfered include, for example, replication and transcription.
  • RNA to be interfered include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA.
  • the overall effect of such interference with target nucleic acid function is modulation of the expression of an encoded product or oligonucleotides.
  • RNA interference "RNAi” is mediated by double stranded RNA (dsRNA) molecules that have sequence- specific homology to their "target" nucleic acid sequences.
  • the mediators are 5-25 nucleotide "small interfering" RNA duplexes (siRNAs).
  • siRNAs are derived from the processing of dsRN A by an RNase enzyme known as Dicer. siRNA duplex products are recruited into a multi-protein siRNA complex termed RISC (RNA Induced Silencing Complex).
  • a RISC is then believed to be guided to a target nucleic acid (suitably mRNA), where the siRNA duplex interacts in a sequence-specific way to mediate cleavage in a catalytic fashion.
  • Small interfering RN As that can be used in accordance with the present invention can be synthesized and used according to procedures that arc well known in the art and that will be familiar to the ordinarily skilled artisan.
  • Small interfering RNAs for use in the methods of the present invention suitably comprise between about 1 to about 50 nucleotides (nt).
  • siRNAs can comprise about 5 to about 40 nt, about 5 to about 30 nt, about 10 to about 30 nt, about 15 to about 25 nt, or about 20-25 nucleotides.
  • oligonucleotides are facilitated by using computer programs that automatically align nucleic acid sequences and indicate regions of identity or homology. Such programs are used to compare nucleic acid sequences obtained, for example, by searching databases such as GenBank or by sequencing PCR products. Comparison of nucleic acid sequences from a range of species allows the selection of nucleic acid sequences that display an appropriate degree of identity between species. In the case of genes that have not been sequenced, Southern blots arc performed to allow a determination of the degree of identity between genes in target species and other species. By performing Southern blots at varying degrees of stringency, as is well known in the art, it is possible to obtain an approximate measure of identity.
  • enzymatic RNA an R A molecule with enzymatic activity (Cech, (1988) J. American. Med. Assoc. 260, 3030-3035).
  • Enzymatic nucleic acids ribozymes act by first binding to a target RNA. Such binding occurs through the target binding portion of an enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA.
  • the enzymatic nucleic acid first recognizes and then binds a target RNA through base pairing, and once bound to the correct site, acts enzymatically to cut the target RNA.
  • decoy RNA an RNA molecule that mimics the natural binding domain for a ligand.
  • the decoy RNA therefore competes with natural binding target for the binding of a specific ligand.
  • TAR HIV trans-activation response
  • the term "monomers” typically indicates monomers linked by phosphodiester bonds or analogs thereof to form oligonucleotides ranging in size from a few monomelic units, e.g., from about 3-4, to about several hundreds of monomelic units.
  • Analogs of phosphodiester linkages include: phosphorothioate, phosphorodithioate, mcthylphosphornatcs, phosphoroselenoate, phosphoramidate, and die like, as more fully described below.
  • nucleotide covers naturally occurring nucleotides as well as nonnaturally occurring nucleotides. It should be clear to the person skilled in the art that various nucleotides which previously have been considered “nonnaturally occurring” have subsequently been found in nature. Thus, “nucleotides” includes not only the known purine and pyrimidinc hctcrocycles-containing molecules, but also heterocyclic analogues and tautomers thereof.
  • nucleotides are molecules containing adenine, guanine, thymine, cytosine, uracil, purine, xanthine, diaminopiirine, 8-oxo- N6-mcthyladenine, 7-deazaxanthine, 7-deazaguanine, N4,N4-ethanocytosin, N6.N6- cthano-2,6- diaminopurinc, 5-mcthylcytosinc, 5-(C3-C6)-alkynylcytosine, 5-fiuorouracil, 5-bromouracil, pscudoisocytosine, 2-hydroxy-5-mcthyl-4-triazolopyridin, isocytosinc, isoguanin, inosinc and the "non-naturally occurring" nucleotides described in Bcnncr el «/., U.S.
  • nucleotide is intended to cover every and all of these examples as well as analogues and tautomers thereof.
  • Especially interesting nucleotides arc those containing adenine, guanine, tliymine, cytosine, and uracil, which are considered as the naturally occurring nucleotides in relation to therapeutic and diagnostic application in humans.
  • Nucleotides include the natural 2'-deoxy and 2'- hydroxyl sugars, e.g., as described in Kombcrg and Baker, DNA Replication, 2nd Ed. CFrceman, San Francisco, 1992) as well as their analogs.
  • nucleotides in reference to nucleotides includes synthetic nucleotides having modified base moieties and/or modified sugar moieties (sec e.g., described generally by Scheit, Nucleotide Analogs, John Wiley, New York, 1980; Frcicr & Altmann, ( 1 97) Nticl. Acid. Res., 25(22), 4429- 4443, Toulme, J.J., (2001) Nature Biotechnology 19: 17-18; anoharan M., (1999) Biachemica el Biophysica Acta 1489: 1 17-139; Freier S.
  • Such analogs include synthetic nucleotides designed to enhance binding properties, e.g., duplex or triplex stability, specificity, or the like.
  • hybridization means the pairing of substantially complementary strands of oligomeric compounds.
  • One mechanism of pairing involves hydrogen bonding, which may be Watson-Criek, Hoogstccn or reversed Hoogstecn hydrogen bonding, between complementary nucleoside or nucleotide bases (nucleotides) of the strands of oligomeric compounds.
  • hydrogen bonding which may be Watson-Criek, Hoogstccn or reversed Hoogstecn hydrogen bonding, between complementary nucleoside or nucleotide bases (nucleotides) of the strands of oligomeric compounds.
  • adenine and thymine are complementary nucleotides which pair through the formation of hydrogen bonds.
  • Hybridization can occur under varying circumstances.
  • An antisensc compound is "specifically hybridizable" when binding of the compound to the target nucleic acid interferes with the normal function of the target nucleic acid to cause a modulation of function and/or activity, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target nucleic acid sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and under conditions in which assays are performed in the case of in vitro assays.
  • stringent hybridization conditions refers to conditions under which a compound of the invention will hybridize to its target sequence, but to a minimal number of other sequences. Stringent conditions arc sequence-dependent and will be different in different circumstances and in the context of this invention, "stringent conditions" under which oligomeric compounds hybridize to a target sequence are determined by the nature and composition of the oligomeric compounds and the assays in which they arc being investigated. In general, stringent hybridization conditions comprise low concentrations ( ⁇ 0.15M) of salts with inorganic cations such as Na++ or K.++ (i.e., low ionic strength), temperature higher than 20°C - 25° C.
  • inorganic cations such as Na++ or K.++ (i.e., low ionic strength
  • the hybridization rate decreases 1.1 % for each 1% formamide.
  • An example of a high stringency hybridization condition is 0.1X sodium chloride-sodium citrate buffer (SSC)/0.1% (w/v) SDS at 60° C. for 30 minutes.
  • Complementary refers to the capacity for precise pairing between two nucleotides on one or two oligomeric strands. For example, if a nucleobasc at a certain position of an antisensc compound is capable of hydrogen bonding with a nuclcobasc at a certain position of a target nucleic acid, said target nucleic acid being a DNA, RNA, or oligonucleotide molecule, then the position of hydrogen bonding between the oligonucleotide and the target nucleic acid is considered to be a complementary position.
  • the oligonicric compound and the further DNA, RNA, or oligonucleotide molecule arc complementary to each other when a sufficient number of complementary positions in each molecule arc occupied by nucleotides which can hydrogen bond with each other.
  • “specifically hybridizablc” and “complementary” are terms which arc used to indicate a sufficient degree of precise pairing or complementarity over a sufficient number of nucleotides such that stable and specific binding occurs between the oligomeric compound and a target nucleic acid.
  • an oligomeric compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizablc.
  • an oligonucleotide may hybridize over one or more segments such that intervening or adjacent segments arc not involved in the hybridization event (e.g., a loop structure, mismatch or hairpin structure).
  • the oligomeric compounds of the present invention comprise at least about 70%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%, or at least about 99% sequence complementarity to a target region within the target nucleic acid sequence to which they are targeted.
  • an antisense compound in which 18 of 20 nucleotides of the antisense compound are complementary to a target region, and would therefore specifically hybridize would represent 90 percent complementarity.
  • the remaining non-complementary nucleotides may be clustered or interspersed with complementary nucleotides and need not be contiguous to each other or to complementary nucleotides.
  • an antisense compound which is 18 nucleotides in length having 4 (four) non-complementary nucleotides which are flanked by two regions of complete complementarity with the target nucleic acid would have 77.8% overall complementarity with the target nucleic acid and would thus fall within the scope of the present invention.
  • Percent complementarity of an antisense compound with a region of a target nucleic acid can be determined routinely using BLAST programs (basic local alignment search tools) and PowcrBLAST programs known in the art. Percent homology, sequence identity or complementarity, can be determined by, for example, the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wis.), using default settings, which uses the algorithm of Smith and Waterman (Adv. Appl. Math., (1981) 2, 482-489).
  • the term "Thermal Melting Point (Tm)” refers to the temperature, under defined ionic strength, pH, and nucleic acid concentration, at which 50% of the oligonucleotides complementary to the target sequence hybridize to the target sequence at equilibrium.
  • stringent conditions will be those in which the salt concentration is at least about 0.01 to 1.0 M Na ion concentration (or other salts) at pH 7.0 to 8.3 and die temperature is at least about 30°C for short oligonucleotides (e.g., 10 to 50 nucleotide). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.
  • “modulation” means either an increase (stimulation) or a decrease (inhibition) in the expression of a genc.
  • variants when used in the context of a polynucleotide sequence, may encompass a polynucleotide sequence related to a wild type gene. This definition may also include, for example, "allelic,” “splice,” “species,” or “polymorphic” variants.
  • a splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during m NA processing.
  • the corresponding polypeptide may possess additional functional domains or an absence of domains.
  • Species variants are polynucleotide sequences that vary from one species to another. Of particular utility in the invention arc variants of wild type genc products.
  • Variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. Any given natural or recombinant genc may have none, one, or many allelic forms. Common mutational changes that give rise to variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.
  • a polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs,) or single base mutations in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population with a propensity for a disease state, that is susceptibility versus resistance.
  • Derivative polynucleotides include nucleic acids subjected to chemical modification, for example, replacement of hydrogen by an alkyl, acyl, or amino group.
  • Derivatives e.g., derivative oligonucleotides, may comprise non- naturally-occurring portions, such as altered sugar moieties or inter-sugar linkages. Exemplary among these are phosphorothioatc and other sulfur containing species which are known in the art.
  • Derivative nucleic acids may also contain labels, including radionuclcotidcs, enzymes, fluorescent agents, chemiluminescent agents, chromogcnic agents, substrates, cofactors, inhibitors, magnetic particles, and the like.
  • a “derivative" polypeptide or peptide is one that is modified, for example, by glycosylation, pcgylation, phosphorylation, sulfation, reduction/alkylation, acylation, chemical coupling, or mild formalin treatment.
  • a derivative may also be modified to contain a detectable label, cither directly or indirectly, including, but not limited to. a radioisotope, fluorescent, and enzyme label.
  • animal or "patient” is meant to include, for example, humans, sheep, elks, deer, mule deer, minks, mammals, monkeys, horses, cattle, pigs, goats, dogs, cats, rats, mice, birds, chicken, reptiles, fish, insects and arachnids.
  • Treating covers warm blooded mammals that are typically under medical care (e.g., humans and domesticated animals). Examples include feline, canine, equine, bovine, and human, as well as just human.
  • Treating covers the treatment of a disease-state in a mammal, and includes: (a) preventing the discasc-statc from occurring in a mammal, in particular, when such mammal is predisposed to the disease-state but has not yet been diagnosed as having it; (b) inhibiting the discasc-statc, e.g., arresting it development; and/or (c) relieving the discasc-statc, e.g., causing regression of the disease state until a desired endpoint is reached. Treating also includes the amelioration of a symptom of a disease (e.g., lessen the pain or discomfort), wherein such amelioration may or may not be directly affecting the disease (e.g., cause, transmission
  • cancer refers to all types of cancer or neoplasm or malignant tumors found in mammals, including, but not limited to: leukemias, lymphomas, melanomas, carcinomas and sarcomas. The cancer manifests itself as a “tumor” or tissue comprising malignant cells of the cancer.
  • tumors include sarcomas and carcinomas such as, but not limited to: fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, cndothcliosarcoma, lymphangiosarcoma, lymphangiocndothcliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma.
  • sarcomas and carcinomas such as, but not limited to: fibrosarcoma, myxosarcom
  • medullary carcinoma bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' rumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, and retinoblastoma.
  • Additional cancers which can be treated by the disclosed composition according to the invention include but not limited to, for example, Hodgkin's Disease, Non-Hodgkin's Lymphoma, multiple myeloma, neuroblastoma, breast cancer, ovarian cancer, lung cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulincmia, small-cell lung rumors, primary brain tumors, stomach cancer, colon cancer, malignant pancreatic insulanoma, malignant carcinoid, urinary bladder cancer, gastric cancer, prcmalignant skin lesions, testicular cancer, lymphomas, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary tract cancer, malignant hypercalcemia, cervical cancer, endometrial cancer, adrenal cortical cancer, and prostate cancer.
  • apoptosis means programmed cell death. It also means “cell death” or “targeted cell death” which occurs in the context of administration of an antisensc oligonucleotide recited herein to treat or mitigate diseases or disorders associated with uncontrolled cell growth and/or the malfunction of normal apoptosis and/or apoptotic pathways.
  • Neurological disease or disorder refers to any disease or disorder of the nervous system and/or visual system.
  • Neurological disease or disorder include disease or disorders that involve the central nervous system (brain, brainstem and cerebellum), the peripheral nervous system (including cranial nerves), and the autonomic nervous system (parts of which are located in both central and peripheral nervous system).
  • a Neurological disease or disorder includes but is not limited to acquired epileptiform aphasia; acute disseminated encephalomyelitis; adrenolcukodystrophy; agc-rclatcd macular degeneration; agenesis of the corpus callosum; agnosia; Aicardi syndrome; Alexander disease; Alpcrs' disease; alternating hemiplegia; Alzheimer's disease; Vascular dementia; amyotrophic lateral sclerosis; ancnccphaly; Angclman syndrome; angiomatosis; anoxia; aphasia; apraxia; arachnoid cysts; arachnoiditis; Anronl-Chiari malformation; arteriovenous malformation; Asperger syndrome; ataxia tclcgicctasia; attention deficit hyperactivity disorder; autism; autonomic dysfunction; back pain; Batten disease; Behcet's disease; Bell's palsy
  • a "proliferative disease or disorder” includes, but is not limited to, hematopoietic neoplastic disorders involving hyperplastic/neoplastic cells of hematopoietic origin arising from myeloid, lymphoid or crythroid lineages, or precursor cells thereof.
  • erythroblastic leukemia include, but arc not limited to erythroblastic leukemia, acute promycloid leukemia (APML), chronic myelogenous leukemia (CML), lymphoid malignancies, including, but not limited to, acute lymphoblastic leukemia (ALL), which includes B-lineagc ALL and T-lincagc ALL, chronic lymphocytic leukemia (CLL), prolymphocyte leukemia (PLL), hairy cell leukemia (HLL) and Waldenstrom's macroglobulinemia (WM).
  • ALL acute lymphoblastic leukemia
  • CLL chronic lymphocytic leukemia
  • PLL prolymphocyte leukemia
  • HLL hairy cell leukemia
  • WM Waldenstrom's macroglobulinemia
  • malignant lymphomas include, but are not limited to, non- Hodgkin lymphoma and variants thereof, peripheral T cell lymphomas, adult T cell leukemia lymphoma (ATL), cutaneous T-ccll lymphoma (CTCL), large granular lymphocytic leukemia (LGF), Hodgkin's disease and Rced- Sternberg disease.
  • ATL adult T cell leukemia lymphoma
  • CCL cutaneous T-ccll lymphoma
  • LGF large granular lymphocytic leukemia
  • Hodgkin's disease Hodgkin's disease and Rced- Sternberg disease.
  • a "hematological disease or disorder” includes a disease, disorder, or condition which affects a hematopoietic cell or tissue.
  • Hematological disorders include diseases, disorders, or conditions associated with aberrant hematological content or function. Examples of hematological disorders include disorders resulting from bone marrow irradiation or chemotherapy treatments for cancer, disorders such as pernicious anemia, hemorrhagic anemia, hemolytic anemia, aplastic anemia, sickle cell anemia, sideroblastic anemia, anemia associated with chronic infections such as malaria, trypanosomiasis, HIV, hepatitis virus or other viruses, myelophthisic anemias caused by marrow deficiencies, renal failure resulting from anemia, anemia, polycethemia, infectious mononucleosis (IM), acute non-lymphocytic leukemia (ANLL), acute Myeloid Leukemia (A L), acute promyelocyte leukemia (APL), acute myelomonocytic leukemia
  • Lymphatic diseases include, but arc not limited to, lymphadenitis, lymphagicctasis, lymphangitis, lymphedema, lymphocclc, lymphoproliferative disorders, mucocutaneous lymph node syndrome, reticuloendotheliosis, splenic diseases, thymus hyperplasia, thymus neoplasms, tuberculosis, lymph node, pseudolymphoma, and lymphatic abnormalities.
  • Disorders of hcmatolymphoid system include, but arc not limited to. non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and reactive lymphoid hyperplasia.
  • the targets comprise nucleic acid sequences of BCL2-likc 1 1 (BCL2L 1 1 ), including without limitation sense and/or antisense noncoding and/or coding sequences associated with BCL2L 1 I .
  • BCL2L 1 1 members of the Bcl-2 family of proteins arc structurally similar, but have divergent activities. This family of proteins is divided into the "pro-apoptotic" family members (i.e., Bax, Bak, Bok), and the "pro-survival” family members (i.e., Bcl-2, Bel-XL, Bcl-w). The former can be further subdivided into those proteins containing the BH3 domain and those lacking it. The BH3 domain is thought to facilitate binding of these proteins directly to members of the "pro-survival” proteins, thereby inhibiting the "pro-survival” activity and promoting cell death or apoptosis.
  • the human BCL2L1 1 locus located on chromosome 2q 13, encodes a protein of 198 amino acids structurally and functionally related to the Bi-D-only group of pro-apoptotic BCL2 family members.
  • the gene is frequently mutated in diverse human tumors leading to loss of BCL2LI 1 activity.
  • Expression of BCL2L 1 1 is induced by a diverse range of apoptotic stimuli such as deprivation of growth factors/cytokines, ionizing radiation, and cytotoxic peptides.
  • antisense oligonucleotides are used to prevent or treat diseases or disorders associated with BCL2L1 1 family members.
  • Exemplary BCL2-likc I I (BCL2LU) mediated diseases and disorders which can be treated with cell/tissues regenerated from stem cells obtained using the antisense compounds comprise: cancer, aberrant apoptosis, a proliferative disease or disorder, a disease or disorder associated with mitochondrial apoptosis pathway, leukemia, an autoimmune disease or disorder, a disease or disorder associated with impaired immunity, infection, hyperproliferative disorders, hyperproliferation of reproductive tissue (such as uterine, testicular and ovarian carcinomas, endometriosis, and squamous, glandular epithelial carcinomas of the cervix etc.), a neurological disease or disorder, a developmental disorder associated with the developing embryo, a hematological disease or disorder, impaired tissue homeostatis, rheumatoid arthritis, sepsis
  • reproductive tissue such
  • modulation of BCL2L1 1 by one or more antisense oligonucleotides is administered to a patient in need thereof, to prevent or treat any disease or disorder related to BCL2L 1 1 abnormal expression, function, activity as compared to a normal control.
  • the oligonucleotides are specific for polynucleotides of BCL2L1 1 , which includes, without limitation noncoding regions.
  • the BCL2LI 1 targets comprise variants of BCL2L 1 1 ; mutants of BCL2LI 1, including SNPs; noncoding sequences of BCL2L1 1 ; alleles, fragments and the like.
  • the oligonucleotide is an antisense RNA molecule.
  • the target nucleic acid molecule is not limited to BCL2L1 1 polynucleotides alone but extends to any of the isoforms, receptors, homologs, non-coding regions and the like of BCL2L1 1.
  • an oligonucleotide targets a natural antisensc sequence (natural antisense to the coding and non-coding regions) of BCL2L 1 1 targets, including, without limitation, variants, alleles, homologs, mutants, derivatives, fragments and complementary sequences thereto.
  • the oligonucleotide is an antisense RNA or DNA molecule.
  • the oligomcric compounds of the present invention also include variants in which a different base is present at one or more of the nucleotide positions in the compound.
  • homology, sequence identity or complementarity, between the antisense compound and target is from about 50% to about 60%. In some embodiments, homology, sequence identity or complementarity, is from about 60% to about 70%. In some embodiments, homology, sequence identity or complementarity, is from about 70% to about 80%.
  • homology, sequence identity or complementarity is from about 80% to about 90%. In some embodiments, homology, sequence identity or complementarity, is about 90%, about 92%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about 100%.
  • An antisense compound is specifically hybridizable when binding of the compound to the target nucleic acid interferes with the normal function of the target nucleic acid to cause a loss of activity, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target nucleic acid sequences under conditions in which specific binding is desired.
  • Such conditions include, i.e., physiological conditions in the case of in vivo assays or therapeutic treatment, and conditions in which assays are performed in the case of in vitro assays.
  • An antisense compound whether DNA, NA, chimeric, substituted etc, is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complcmcntarily to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays arc performed.
  • targeting of BCL2L 1 1 including without limitation, antisense sequences which arc identified and expanded, using for example, PCR, hybridization etc., one or more of the sequences set forth as SEQ ID NOS: 2 and 3, and the like, modulate the expression or function of BCL2L1 1.
  • expression or function is up-regulatcd as compared to a control.
  • expression or function is down-regulated as compared to a control.
  • oligonucleotides comprise nucleic acid sequences set forth as SEQ ID NOS: 4 to 13 including antisense sequences which arc identified and expanded, using for example, PCR, hybridization etc. These oligonucleotides can comprise one or more modified nucleotides, shorter or longer fragments, modified bonds and the like. Examples of modified bonds or intemucleotide linkages comprise phosphorothioate, phosphorodithioatc or the like. In an embodiment, the nucleotides comprise a phosphorus derivative.
  • the phosphorus derivative (or modified phosphate group) which may be attached to the sugar or sugar analog moiety in the modified oligonucleotides of the present invention may be a monophosphate, diphosphate, triphosphate, alkylphosphatc, alkancphosphatc, phosphorothioatc and the like.
  • the preparation of the above-noted phosphate analogs, and their incorporation into nucleotides, modified nucleotides and oligonucleotides, per sc, is also known and need not be described here.
  • Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotides have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans.
  • Jn embodiments of the present invention oligomeric antisense compounds, particularly oligonucleotides, bind to target nucleic acid molecules and modulate the expression and/or function of molecules encoded by a target gene.
  • the functions of DNA to be interfered comprise, for example, replication and transcription.
  • the functions of RNA to be interfered comprise all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA.
  • the functions may be up-regulated or inhibited depending on the functions desired.
  • the antisense compounds include, antisense oligomeric compounds, antisense oligonucleotides, external guide sequence (EGS) oligonucleotides, alternate splicers, primers, probes, and other oligomeric compounds that hybridize to at least a portion of the target nucleic acid. As such, these compounds may be introduced in the form of single-stranded, double-stranded, partially single-stranded, or circular oligomeric compounds.
  • EGS external guide sequence
  • Targeting an antisense compound to a particular nucleic acid molecule can be a multistep process.
  • the process usually begins with the identification of a target nucleic acid whose function is to be modulated.
  • This target nucleic acid may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent.
  • the target nucleic acid encodes BCL2-like 1 1 (BCL2L11).
  • the targeting process usually also includes determination of at least one target region, segment, or site within the target nucleic acid for the antisense interaction to occur such that the desired effect, e.g., modulation of expression, will result.
  • region is defined as a portion of the target nucleic acid having at least one identifiable structure, function, or characteristic.
  • regions of target nucleic acids arc segments.
  • Segments arc defined as smaller or sub-portions of regions within a target nucleic acid.
  • Sites as used in the present invention, arc defined as positions within a target nucleic acid.
  • the antisense oligonucleotides bind to the natural antisense sequences of BCL2-like 1 1 (BCL2L1 1) and modulate the expression and/or function of BCL2LI I (SEQ ID NO: 1).
  • antisense sequences include SEQ ID NOS: 2 to 13.
  • the antisense oligonucleotides bind to one or more segments of BCL2-likc 1 1 (BCL2L 1 1 ) polynucleotides and modulate the expression and/or function of BCL2L1 1.
  • the segments comprise at least five consecutive nucleotides of the BCL2L 11 sense or antisense polynucleotides.
  • the antisense oligonucleotides are specific for natural antisense sequences of BCL2L1 1 wherein binding of the oligonucleotides to the natural antisense sequences of BCL2L1 1 modulate expression and/or function of BCL2Ll l .
  • oligonucleotide compounds comprise sequences set forth as SEQ ID NOS: 4 to 13, antisense sequences which are identified and expanded, using for example, PCR, hybridization etc
  • These oligonucleotides can comprise one or more modified nucleotides, shorter or longer fragments, modified bonds and the like. Examples of modified bonds or intcmucleotide linkages comprise phosphorothioate, phosphorodithioate or the like.
  • the nucleotides comprise a phosphorus derivative.
  • the phosphorus derivative (or modified phosphate group) which may be attached to the sugar or sugar analog moiety in the modified oligonucleotides of the present invention may be a monophosphate, diphosphate, triphosphate, alkylphosphate. alkanephosphatc, phosphorothioate and the like.
  • the preparation of the above-noted phosphate analogs, and their incorporation into nucleotides, modified nucleotides and oligonucleotides, perse, is also known and need not be described here.
  • the translation initiation codon is typically 5 -AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon,” the “start codon” or the “AUG start codon”.
  • a minority of genes has a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG; and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function in vivo.
  • translation initiation codon and “start codon” can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in cukaryotcs) or fonnylmcthionine (in prokaryotcs).
  • Eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions.
  • start codon and “translation initiation codon” refer to the codon or codons that are used in vivo to initiate translation of an mRNA transcribed from a gene encoding BCL2-likc 1 1 (BCL2LI I ), regardless of the sequcnce(s) of such codons.
  • a translation termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5 -UAA, 5 -UAG and 5 -UGA (the corresponding DNA sequences arc 5'- TAA, 5'- TAG and 5'-TGA, respectively).
  • start codon region and “translation initiation codon region” refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon.
  • stop codon region and “translation termination codon region” refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in cither direction (i.e., 5' or 3') from a translation termination codon. Consequently, the "start codon region” (or “translation initiation codon region”) and the “stop codon region” (or 'translation termination codon region”) arc all regions that may be targeted effectively with the antiscnsc compounds of the present invention.
  • a targeted region is the intragenic region encompassing the translation initiation or termination codon of the open reading frame (ORF) of a gene.
  • Another target region includes the 5' untranslated region (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA (or corresponding nucleotides on the gene).
  • Still another target region includes the 3' untranslated region (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA (or corresponding nucleotides on the gene).
  • the 5' cap site of an mRNA comprises an N7-methylatcd guanosinc residue joined to the 5'-most residue of the mRNA via a 5'-5 * triphosphate linkage.
  • the 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap site.
  • Another target region for this invention is the 5' cap region.
  • mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which arc excised from a transcript before it is translated. The remaining (and therefore translated) regions are known as “exons" and arc spliced together to form a continuous mRNA sequence.
  • targeting splice sites i.e., intron-exon junctions or exon-intron junctions, is particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a particular splice product is implicated in disease.
  • An aberrant fusion junction due to rearrangement or deletion is another embodiment of a target site.
  • mRNA transcripts produced via the process of splicing of two (or more) mRNAs from different gene sources arc known as "fusion transcripts". Introns can be effectively targeted using antisense compounds targeted to, for example, DNA or prc-mRNA.
  • the antisense oligonucleotides bind to coding and/or non-coding regions of a target polynucleotide and modulate the expression and/or function of the target molecule.
  • the antiscnse oligonucleotides bind to natural antiscnsc polynucleotides and modulate the expression and/or function of the target molecule.
  • the antiscnsc oligonucleotides bind to sense polynucleotides and modulate the expression and/or function of the target molecule.
  • transcripts can be produced from the same genomic region of DNA. These alternative transcripts are generally known as "variants”. More specifically, “pre-mRNA variants” are transcripts produced from the same genomic DNA that differ from other transcripts produced from the same genomic DNA in cither their start or stop position and contain both intronic and exonic sequence.
  • pre-mRNA variants Upon excision of one or more exon or intron regions, or portions thereof during splicing, pre-mRNA variants produce smaller "mRNA variants". Consequently, mRNA variants are processed pre-mRNA variants and each unique pre-mRNA variant must always produce a unique mRNA variant as a result of splicing. These mRNA variants are also known as "alternative splice variants". If no splicing of the pre-mRNA variant occurs then the pre-mRNA variant is identical to the mRNA variant.
  • Variants can be produced through the use of alternative signals to start or stop transcription. Prc-mRNAs and inRNAs can possess more than one start codon or stop codon. Variants that originate from a pre-mRNA or mRNA that use alternative start codons are known as "alternative start variants" of that pre-mRNA or mRNA. Those transcripts that use an alternative stop codon arc known as “alternative stop variants" of that pre-mRNA or mRNA.
  • One specific type of alternative stop variant is the "polyA variant” in which the multiple transcripts produced result from the alternative selection of one of the "polyA stop signals" by the transcription machinery, thereby producing transcripts that terminate at unique polyA sites.
  • the types of variants described herein are also embodiments of target nucleic acids.
  • the locations on the target nucleic acid to which the antisense compounds hybridize pre defined as at least a 5-nucleotide long portion of a target region to which an active antisense compound is targeted.
  • Target segments 5-100 nucleotides in length comprising a stretch of at least five (5) consecutive nucleotides selected from within the illustrative preferred target segments arc considered to be suitable for targeting as well.
  • Target segments can include DNA or RNA sequences that comprise at least the 5 consecutive nucleotides from the 5'-tcrminus of one of the illustrative preferred target segments (the remaining nucleotides being a consecutive stretch of the same DNA or RNA beginning immediately upstream of the 5'-terminus of the target segment and continuing until the DNA or RNA contains about 5 to about 100 nucleotides).
  • preferred target segments are represented by DNA or RNA sequences that comprise at least the 5 consecutive nucleotides from the 3'-terminus of one of the illustrative preferred target segments (.the remaining nucleotides being a consecutive stretch of the same DNA or RNA beginning immediately downstream of the 3'-tcrminus of the target segment and continuing until the DNA or RNA contains about 5 to about 100 nucleotides).
  • One having skill in the art armed with the target segments illustrated herein will be able, without undue experimentation, to identify further preferred target segments.
  • antiscnsc compounds arc chosen which arc sufficiently complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.
  • the oligonucleotides bind to an antisense strand of a particular target.
  • the oligonucleotides arc at least 5 nucleotides in length and can be synthesized so each oligonucleotide targets overlapping sequences such that oligonucleotides arc synthesized to cover the entire length of the target polynucleotide.
  • the targets also include coding as well as non coding regions.
  • Targeting an antiscnsc compound to a particular nucleic acid is a multistcp process.
  • the process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a non coding polynucleotide such as for example, non coding RNA (ncR A).
  • RNAs can be classified into (1 ) messenger RNAs (mRNAs), which are translated into proteins, and (2) non- protein-coding R As (ncRNAs).
  • ncRNAs comprise microRNAs, antisense transcripts and other Transcriptional Units (TU) containing a high density of stop codons and lacking any extensive "Open Reading Frame".
  • TU Transcriptional Units
  • Many ncRNAs appear to start from initiation sites in 3' untranslated regions (3'UTRs) of protein-coding loci. ncRNAs arc often rare and at least half of the ncRNAs that have been sequenced by the FANTOM consortium seem not to be polyadenylated.
  • ncRNAs may regulate gene expression is by base pairing with target transcripts.
  • RNAs that function by base pairing can be grouped into (1) cis encoded RNAs that arc encoded at the same genetic location, but on the opposite strand to the RNAs they act upon and therefore display perfect complementarity to their target, and (2) trans-encoded RNAs that arc encoded at a chromosomal location distinct from the RNAs they act upon and generally do not exhibit perfect base-pairing potential with their targets.
  • perturbation of an antisense polynucleotide by the antisense oligonucleotides described herein can alter the expression of the corresponding sense messenger RNAs.
  • this regulation can cither be discordant (antisense knockdown results in messenger RNA elevation) or concordant (antiscnsc knockdown results in concomitant messenger RNA reduction).
  • antiscnsc oligonucleotides can be targeted to overlapping or non-overlapping parts of the antisense transcript resulting in its knockdown or sequestration.
  • Coding as well as non-coding antisense can be targeted in an identical manner and that eitlier category is capable of regulating the corresponding sense transcripts - either in a concordant or disconcordant manner.
  • the strategics that arc employed in identifying new oligonucleotides for use against a target can be based on the knockdown of antisense RNA transcripts by antisense oligonucleotides or any other means of modulating the desired target.
  • Strategy 1 In the case of discordant regulation, knocking down the antisense transcript elevates the expression of the conventional (sense) gene. Should that latter gene encode for a known or putative drug target, then knockdown of its antisense counterpart could conceivably mimic the action of a receptor agonist or an enzyme stimulant.
  • antisense compounds include antisense oligonucleotides, ribozymes, external guide sequence (EGS) oligonucleorides, siRNA compounds, single- or double-stranded RNA interference (RNAi) compounds such as siRNA compounds, and other oligomeric compounds which hybridize to at least a portion of the target nucleic acid and modulate its function.
  • they may be DNA, RNA, DNA-like, RNA-!ike, or mixtures thereof, or may be mimctics of one or more of these.
  • These compounds may be single-stranded, doublcstranded, circular or hairpin oligomeric compounds and may contain structural elements such as internal or terminal bulges, mismatches or loops.
  • Antisense compounds are routinely prepared linearly but can be joined or otherwise prepared to be circular and/or branched.
  • Antisense compounds can include constructs such as, for example, two strands hybridized to form a wholly or partially doub!c-stranded compound or a single strand with sufficient sclf- complcmcntarity to allow for hybridization and formation of a fully or partially double-stranded compound.
  • the two strands can be linked internally leaving free 3' or 5' termini or can be linked to form a continuous hairpin structure or loop.
  • the hairpin structure may contain an overhang on cither the 5' or 3' terminus producing an extension of single stranded character.
  • the double stranded compounds optionally can include overhangs on the ends.
  • dsRNA can take the fonn of a self-complementary hairpin-rypc molecule that doubles back on itself to form a duplex.
  • the dsRNAs can be fully or partially double stranded. Specific modulation of gene expression can be achieved by stable expression of dsRNA hairpins in transgenic cell lines, however, in some embodiments, the gene expression or function is up regulated.
  • the two strands When formed from two strands, or a single strand that takes the form of a self-complementary hairpin-type molecule doubled back on itself to form a duplex, the two strands (or duplex-forming regions of a single strand) arc complementary RNA strands that base pair in Watson-Crick fashion.
  • nucleic acids including oligonucleotides
  • DNA-likc i.e., generally having one or more 2'-deoxy sugars and, generally, T rather than U bases
  • RNA-likc i.e., generally having one or more 2'- hydroxyl or 2'-modified sugars and, generally U rather than T bases
  • Nucleic acid helices can adopt more than one type of stmcture, most commonly the A- and B-forms.
  • an antisense compound may contain both A- and B-form regions.
  • the desired oligonucleotides or antisense compounds comprise at least one of: antisense RNA, antisense DNA, chimeric antisense oligonucleotides, antisense oligonucleotides comprising modified linkages, interference RNA (RNAi), short interfering RNA (siRNA); a micro, interfering RNA (miRNA); a small, temporal RNA (stRN A); or a short, hairpin RNA (shRNA); small RNA-induced gene activation (RNAa); small activating RNAs (saRNAs), or combinations thereof
  • RNAa small RNA-induced gene activation
  • dsRNAs targeting gene promoters induce potent transcriptional activation of associated genes.
  • RNAa was demonstrated in human cells using synthetic dsRNAs, termed “small activating RNAs” (saRNAs). It is currently not known whether RNAa is conserved in other organisms.
  • RNAi small interfering RNA
  • miRNA microRNA
  • RNAi RNA interference
  • oligonucleotides arc shown to increase the expression and/or function of the BCL2-likc 1 1 (BCL2L 1 1) polynucleotides and encoded products thereof.
  • dsRNAs may also act as small activating RNAs (saRNA).
  • saRNA small activating RNAs
  • the "preferred target segments” identified herein may be employed in a screen for additional compounds that modulate the expression of BCL2-like 1 1 (BCL2L1 1) polynucleotides.
  • “Modulators” arc those compounds tliat decrease or increase the expression of a nucleic acid molecule encoding BCL2L 11 and which comprise at least a 5-nucleotidc portion that is complemeatary to a preferred target segment.
  • the screening method comprises the steps of contacting a preferred target segment of a nucleic acid molecule encoding sense or natural antisense polynucleotides of BCL2L1 1 with one or more candidate modulators, and selecting for one or more candidate modulators which decrease or increase the expression of a nucleic acid molecule encoding BCL2L1 1 polynucleotides, e.g. SEQ ID NOS: 4 to 13.
  • the candidate modulator or modulators arc capable of modulating (e.g.
  • the modulator may then be employed in further investigative studies of the function of BCL2L1 1 polynucleotides, or for use as a research, diagnostic, or therapeutic agent in accordance with the present invention.
  • Targeting the natural antisense sequence preferably modulates the function of the target gene.
  • the BCL2L1 1 gene e.g. accession number NM_207002.
  • the target is an antisense polynucleotide of the BCL2L 1 1 gene.
  • an antisense oligonucleotide targets sense and/or natural antisense sequences of BCL2LI I polynucleotides (e.g. accession number NM_207002), variants, alleles, isoforms, homologs, mutants, derivatives, fragments and complementary sequences thereto.
  • the oligonucleotide is an antisense molecule and the targets include coding and noncoding regions of antisense and/or sense BCL2L11 polynucleotides.
  • the preferred target segments of the present invention may be also be combined with their respective complementary antisense compounds of the present invention to form stabilized double-stranded (duplexed) oligonucleotides.
  • Double stranded oligonucleotide moieties have been shown in the art to modulate target expression and regulate translation as well as RNA processing via an antisense mechanism. Moreover, the double-stranded moieties may be subject to chemical modifications. For example, such double-stranded moieties have been shown to inhibit the target by the classical hybridization of antisense strand of the duplex to the target, thereby triggering enzymatic degradation of the target.
  • an antisense oligonucleotide targets BCL2-like 1 1 (BCL2L1 1 ) polynucleotides (e.g. accession number NM_207002), variants, alleles, isoforms, homologs, mutants, derivatives, fragments and complementary sequences thereto.
  • BCL2L1 1 BCL2-like 1 1 polynucleotides
  • the oligonucleotide is an antisense molecule.
  • the target nucleic acid molecule is not limited to BCL2L 1 1 alone but extends to any of the isoforms, receptors, homologs and the like of BCL2L1 1 molecules.
  • an oligonucleotide targets a natural antisense sequence of BCL2L1 1 polynucleotides, for example, polynucleotides set forth as SEQ ID NOS: 2 and 3, and any variants, alleles, homologs, mutants, derivatives, fragments and complementary sequences thereto.
  • antisense oligonucleotides arc set forth as SEQ ID NOS. 4 to 13.
  • the oligonucleotides arc complementary to or bind to nucleic acid sequences of BCL2L1 1 antisense, including without limitation noncoding sense and/or antisense sequences associated with BCL2L1 1 polynucleotides and modulate expression and/or function of BCL2L1 1 molecules.
  • the oligonucleotides are complementary to or bind to nucleic acid sequences of BCL2L 1 1 natural antisense. set forth as SEQ ID NOS: 2 and 3, and modulate expression and/or function of BCL2L1 1 molecules.
  • oligonucleotides comprise sequences of at least 5 consecutive nucleotides of SEQ ID NOS: 4 to 13 and modulate expression and/or function of BCL2L 1 1 molecules.
  • the polynucleotide targets comprise BCL2L 1 1 , including family members thereof, variants of BCL2L11 ; mutants of BCL2L 1 1 , including SNPs; noncoding sequences of BCL2L1 1 ; alleles of BCL2L 1 1 ; species variants, fragments and the like.
  • the oligonucleotide is an antisense molecule.
  • the oligonucleotide targeting BCL2LI 1 polynucleotides comprise: antisense RNA, interference RNA (R Ai), short interfering RNA (siRNA); micro interfering RNA (miRNA); a small, temporal RNA (stRNA); or a short, hairpin RNA (shRNA); small RNA-induced gene activation (RNAa); or, small activating RNA (saRNA).
  • R Ai interference RNA
  • siRNA short interfering RNA
  • miRNA micro interfering RNA
  • shRNA small, temporal RNA
  • shRNA small RNA-induced gene activation
  • RNAa small activating RNA
  • targeting of BCL2-like I I (BCL2LI 1 ) polynucleotides modulate the expression or function of these targets.
  • expression or function is up-rcgulatcd as compared to a control.
  • expression or function is down-regulated as compared to a control.
  • antisense compounds comprise sequences set forth as SEQ ID NOS: 4 to 13. These oligonucleotides can comprise one or more modified nucleotides, shorter or longer fragments, modified bonds and the like.
  • SEQ ID NOS: 4 to 13 comprise one or more LNA nucleotides.
  • Table I shows exemplary antisense oligonucleotides useful in the methods of the invention.
  • the modulation of a desired target nucleic acid can be carried out in several ways known in the art. For example, antisense oligonucleotides, siRNA etc.
  • Enzymatic nucleic acid molecules e.g., ribozymcs
  • enzymatic nucleic acid molecules arc nucleic acid molecules capable of catalyzing one or more of a variety of reactions, including the ability to repeatedly cleave other separate nucleic acid molecules in a nucleotide base sequence-specific manner.
  • Such enzymatic nucleic acid molecules can be used, for example, to target virtually any RNA transcript.
  • trans-cleaving enzymatic nucleic acid molecules show promise as therapeutic agents for human disease.
  • Enzymatic nucleic acid molecules can be designed to cleave specific RNA targets within the background of cellular RNA. Such a cleavage event renders the mRNA non-functional and abrogates protein expression from that RNA. In this manner, synthesis of a protein associated with a disease state can be selectively inhibited.
  • enzymatic nucleic acids with RNA cleaving activity act by first binding to a target RNA. Such binding occurs through the target binding portion of an enzymatic nucleic acid which is held in close proximity to an enzymatic portion of the molecule that acts to cleave the target RNA.
  • the enzymatic nucleic acid first recognizes and then binds a target RNA through complementary base pairing, and once bound to the correct site, acts enzymatically to cut the target RNA. Strategic cleavage of such a target RNA will destroy its ability to direct synthesis of an encoded protein. After an enzymatic nucleic acid has bound and cleaved its RNA target, it is released from that RNA to search for another target and can repeatedly bind and cleave new targets.
  • RNA-cleaving ribozymes for the purpose of regulating gene expression.
  • the hammerhead ribozyme functions with a catalytic rate (kcat) of about 1 min-1 in the presence of saturating (10 mM) concentrations of Mg2+ cofactor.
  • An artificial "RNA ligase" ribozyme has been shown to catalyze the corresponding self-modification reaction with a rate of about 100 min-1 .
  • certain modified hammerhead ribozymes that have substrate binding arms made of DNA catalyze RNA cleavage with multiple turn-over rates that approach 100 min- 1.
  • ribozymes can promote chemical transformations with catalytic rates that arc significantly greater than those displayed in vitro by most natural self-cleaving ribozymes. It is then possible that the structures of certain selfcleaving ribozymes may be optimized to give maximal catalytic activity, or that entirely new RNA motifs can be made that display significantly faster rates for RNA phosphodiester cleavage.
  • Catalytic RNAs designed based on the "hammerhead” motif have been used to cleave specific target sequences by making appropriate base changes in the catalytic RNA to maintain necessary base pairing with the target sequences. This has allowed use of the catalytic RNA to cleave specific target sequences and indicates that catalytic RNAs designed according to the "hammerhead” model may possibly cleave specific substrate RNAs in vivo.
  • RNA interference has become a powerful tool for modulating gene expression in mammals and mammalian cells.
  • This approach requires the delivery of small interfering RNA (siRNA) cither as RNA itself or as DNA, using an expression plasmid or virus and the coding sequence for small hairpin RNAs that arc processed to siRNAs.
  • siRNA small interfering RNA
  • This system enables efficient transport of the prc-siRNAs to the cytoplasm where they arc active and permit the use of regulated and tissue specific promoters for gene expression.
  • an oligonucleotide or antisense compound comprises an oligomer or polymer of ribonucleic acid (RNA) and/or deoxyribonucleic acid (DNA), or a mimetic, chimera, analog or homolog thereof.
  • RNA ribonucleic acid
  • DNA deoxyribonucleic acid
  • mimetic, chimera analog or homolog thereof.
  • This term includes oligonucleotides composed of naturally occurring nucleotides, sugars and covalent intemucleoside (backbone) linkages as well as oligonucleotides having non-naturally occurring portions which function similarly.
  • Such modified or substituted oligonucleotides are often desired over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for a target nucleic acid and increased stability in the presence of nucleases.
  • the oligonucleotides or "antisense compounds” include antisense oligonucleotides (e.g. RNA, DNA, mimetic, chimera, analog or homolog thereof), ribozymes, external guide sequence (EGS) oligonucleotides, siRNA compounds, single- or double-stranded RNA interference (RNAi) compounds such as siRNA compounds, saR A, aRNA, and other oligomeric compounds which hybridize to at least a portion of the target nucleic acid and modulate its function.
  • antisense oligonucleotides e.g. RNA, DNA, mimetic, chimera, analog or homolog thereof
  • ribozymes oligonucleotides
  • siRNA compounds single- or double-stranded RNA interference (RNAi) compounds
  • RNAi RNA interference
  • siRNA compounds single- or double-stranded RNA interference
  • siRNA compounds single- or double-stranded RNA interference (RNAi
  • Antisense compounds may be single-stranded, double-stranded, circular or hairpin oligomeric compounds and may contain structural elements such as internal or terminal bulges, mismatches or loops.
  • Antisense compounds are routinely prepared linearly but can be joined or otherwise prepared to be circular and/or branched.
  • Antisense compounds can include constructs such as, for example, two strands hybridized to form a wholly or partially double-stranded compound or a single strand with sufficient sclf-complcmcntarity to allow for hybridization and formation of a fully or partially double-stranded compound.
  • the two strands can be linked internally leaving free 3' or 5' termini or can be linked to form a continuous hairpin structure or loop.
  • the hairpin staicture may contain an overhang on cither the 5' or 3' terminus producing an extension of single stranded character.
  • the double stranded compounds optionally can include overhangs on the ends. Further modifications can include conjugate groups attached to one of the termini, selected nucleotide positions, sugar positions or to one of the intemucleoside linkages. Alternatively, the two strands can be linked via a non-nucleic acid moiety or linker group.
  • dsRNA can take the fonn of a self-complementary hairpin-type molecule that doubles back on itself to form a duplex. Thus, the dsRNAs can be fully or partially double stranded.
  • dsRNA hairpins in transgenic cell lines.
  • the two strands or duplex-forming regions of a single strand
  • RNA strands that base pair in Watson- Crick fashion.
  • nucleic acids including oligonucleotides
  • DNA-likc i.e., generally having one or more 2'-deoxy sugars and, generally, T rather than U bases
  • NA-like i.e., generally having one or more 2'- hydroxyl or 2'-modificd sugars and, generally U rather than T bases.
  • Nucleic acid helices can adopt more than one type of structure, most commonly the A- and B-forms.
  • an antisensc compound may contain both A- and B-form regions.
  • the antisensc compounds in accordance with this invention can comprise an antisensc portion from about 5 to about 80 nucleotides (i.e. from about 5 to about 80 linked nucleosides) in length. This refers to the length of the antisense strand or portion of the antisense compound.
  • a single-stranded antisense compound of the invention comprises from 5 to about 80 nucleotides
  • a double-stranded antisensc compound of the invention (such as a dsRNA, for example) comprises a sense and an antisense strand or portion of 5 to about 80 nucleotides in length.
  • the antisensc compounds of the invention have antisense portions of 10 to 50 nucleotides in length.
  • oligonucleotides having antisensc portions of 10, 1 1. 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28. 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 nucleotides in length, or any range thercwithin.
  • the oligonucleotides arc 15 nucleotides in length.
  • the antisense or oligonucleotide compounds of the invention have antisense portions of 12 or 13 to 30 nucleotides in length.
  • antisensc compounds having antisensc portions of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29 or 30 nucleotides in length, or any range thercwithin.
  • the oligomenc compounds of the present invention also include variants in which a different base is present at one or more of the nucleotide positions in the compound.
  • the first nucleotide is an adenosine
  • variants may be produced which contain thymidine, guanosine or cytidine at this position. This may be done at any of the positions of the antisense or dsRNA compounds. These compounds arc then tested using the methods described herein to determine their ability to inhibit expression of a target nucleic acid.
  • homology, sequence identity or complementarity, between the antisense compound and target is from about 40% to about 60%. In some embodiments, homology, sequence identity or complementarity, is from about 60% to about 70%. In some embodiments, homology, sequence identity or complementarity, is from about 70% to about 80%. In some embodiments, homology, sequence identity or complementarity, is from about 80% to about 90%. In some embodiments, homology, sequence identity or complementarity, is about 90%, about 92%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or about I (X)%.
  • the antisense oligonucleotides such as for example, nucleic acid molecules set forth in SEQ ID NOS: 4 to 13 comprise one or more substitutions or modifications.
  • the nucleotides arc substituted with locked nucleic acids (LNA).
  • the oligonucleotides target one or more regions of the nucleic acid molecules sense and/or antisense of coding and/or non-coding sequences associated with BCL2L 1 1 and the sequences set forth as SEQ ID NOS: 1 to 3.
  • the oligonucleotides are also targeted to overlapping regions of SEQ ID NOS: I to 3.
  • oligonucleotides of this invention are chimeric oligonucleotides.
  • "Chimeric oligonucleotides” or “chimeras,” in the context of this invention, are oligonucleotides which contain two or more chemically distinct regions, each made up of at least one nucleotide. These oligonucleotides typically contain at least one region of modified nucleotides that confers one or more beneficial properties (such as, for example, increased nuclease resistance, increased uptake into cells, increased binding affinity for the target) and a region that is a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids.
  • RNase H is a cellular cndonuclcase which cleaves the RNA strand of an RNA.DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of antisense modulation of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides arc used, compared to phosphorothioate dcoxyoligonuclcotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.
  • a chimeric oligonucleotide comprises at least one region modified to increase target binding affinity, and, usually, a region that acts as a substrate for RNAsc H.
  • Affinity of an oligonucleotide for its target is routinely determined by measuring the Tm of an oligonuclcotidc/targct pair, which is the temperature at which the oligonucleotide and target dissociate; dissociation is detected spcctrophotomctrically. The higher the Tm, the greater is the affinity of the oligonucleotide for the target.
  • Chimeric antisense compounds of the invention may be formed as composite structures of two or more oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotides mimetics as described above. Such; compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures comprise, but arc not limited to, US patent nos.
  • the region of the oligonucleotide which is modified comprises at least one nucleotide modified at the 2' position of the sugar, most preferably a 2'-Oalkyl, 2'-0-alkyl-0-alkyl or 2'-fluoro-modificd nucleotide.
  • RNA modifications include 2'-fluoro, 2'-amino and 2' O-mcthyl modifications on the ribose of pyrimidiues, abasic residues or an inverted base at the 3' end of the RNA.
  • RNAse H is a cellular endonuclease that cleaves the RNA strand of RN A:DNA duplexes; activation of this enzyme therefore results in cleavage of the RNA target, and thus can greatly enhance the efficiency of RNAi inhibition. Cleavage of the RNA target can be routinely demonstrated by gel electrophoresis.
  • the chimeric oligonucleotide is also modified to enhance nuclease resistance.
  • Cells contain a variety of exo- and endo-nuc leases which can degrade nucleic acids. A number of nucleotide and nucleoside modifications have been shown to make the oligonucleotide into which they are incorporated more resistant to nuclease digestion than the native oligodeoxynucleotide.
  • Nuclease resistance is routinely measured by inaibating oligonucleotides with cellular extracts or isolated nuclease solutions and measuring the extent of intact oligonucleotide remaining over time, usually by gel electrophoresis.
  • Oligonucleotides which have been modified to enhance their nuclease resistance survive intact for a longer time than unmodified oligonucleotides.
  • a variety of oligonucleotide modifications have been demonstrated to enhance or confer nuclease resistance.
  • Oligonucleotides which contain at least one phosphorothioatc modification arc presently more preferred.
  • oligonucleotide modifications which enhance target binding affinity arc also, independently, able to enhance nuclease resistance.
  • oligonucleotides envisioned for this invention include those comprising modified backbones, for example, phosphorothioatcs, phosphotriestcrs, methyl phosphonatcs, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages.
  • oligonucleotides with phosphorothioatc backbones and those with heteroatom backbones particularly CH2 -NH--0-- CH2, CH, ⁇ N(CH3)-0--CH2 [known as a mcthy!cncimcthylimino) or MM] backbone], CH2 -0 ⁇ N (CH3>-CH2, CH2 -N (CH3)-N (CH3)-CH2 and O-N (CH3)-CH2 --CH2 backbones, wherein the native phosphodicstcr backbone is represented as 0--P--0-CH,).
  • arc also preferred.
  • arc oligonucleotides having morpholino backbone structures (Summerton and Weller, U.S. Pat. No. 5,034,506).
  • PNA peptide nucleic acid
  • Oligonucleotides having morpholino backbone structures such as the peptide nucleic acid (PNA) backbone
  • PNA peptide nucleic acid
  • the phosphodiester backbone of the oligonucleotide is replaced with a po!yamidc backbone, the nucleotides being bound directly or indirectly to the aza nitrogen atoms of the polyamidc backbone.
  • Oligonucleotides may also comprise one or more substituted sugar moieties.
  • Preferred oligonucleotides comprise one of the following at the 2' position: OH, SH, SCH3, F, OCN, OCH3 OCH3, OCH3 0(CH2)n CH3, 0(CH2)n NH2 or 0(CH2)n CH3 where n is from I to about 10; CI to CIO lower alkyl, alkoxyalkoxy, substituted lower alkyl, alkaryl or aralkyl; CI; Br; CN; CF3 ; OCF3; O--, S--, or N-alkyl; 0-, S-, or N-alkcnyl; SOCH3; S02 CH3; ON02; N02; N3; NH2; hctcrocycloalkyl; hctcrocycloalkaryl; aminoalkylamino; polyalkylamino; substituted silyl; an RNA cleaving group; a reporter group; an intercalator; a group for improving the pharmacokinetic
  • a preferred modification includes 2'-methoxyethoxy
  • Other preferred modifications include 2'-mcthoxy (2'-0--CH3), 2'- propoxy (2'-OCH2 CH2CH3) and 2'-fluoro (2'-F).
  • Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide and the 5' position of 5' terminal nucleotide.
  • Oligonucleotides may also have sugar mimctics such as cyclobutyls in place of the pentofuranosyl group.
  • Oligonucleotides may also include, additionally or alternatively, nucleobase (often referred to in the art simply as “base”) modifications or substitutions.
  • nucleobase often referred to in the art simply as “base”
  • “unmodified” or “natural” nucleotides include adenine (A), guanine (G), thymine (T), cytosine (C) and uracil (U).
  • Modified nucleotides include nucleotides found only infrequently or transiently in natural nucleic acids, e.g., hypoxanthine, 6-methyladenine, 5-Me pyrimidines, particularly 5-methylcytosine (also referred to as 5-methyl-2' deoxycytosine and often referred to in the art as 5-Me-C), 5- hydroxymethylcytosine (HMC), glycosyl HMC and gentobiosyl HMC, as well as synthetic nucleotides, e.g., 2- aminoadenine, 2-(mcthylamino)adenine, 2-(imidazolylalkyl)adenine, 2- (aminoalklyamino)adenine or other hcterosubstituted alkyladenines, 2-thiouracil, 2-thiothymine, 5- bromouracil, 5-hydroxymethyluracil, 8-azaguaninc, 7- dcazaguanine, N6 (6-amin
  • a "universal" base known in the art e.g., inosinc. may be included.
  • 5-Me-C substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C. and arc presently preferred base substitutions.
  • oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates which enhance the activity or cellular uptake of the oligonucleotide.
  • moieties include but are not limited to lipid moieties such as a cholesterol moiety, a cholesteryl moiety, an aliphatic chain, e.g., dodecandiol or undccyl residues, a polyaminc or a polyethylene glycol chain, or Adamanfane acetic acid.
  • Oligonucleotides comprising lipophilic moieties, and methods for preparing such oligonucleotides arc known in the art, for example, U.S. Pat Nos. 5, 138,045, 5,218, 105 and 5,459,255.
  • the present invention also includes oligonucleotides which arc chimeric oligonucleotides as hereinbefore defined.
  • the nucleic acid molecule of the present invention is conjugated with another moiety including but not limited to abasic nucleotides, polycthcr, polyaminc, polyamidcs, peptides, carbohydrates, lipid, or polyhydrocarbon compounds. Those skilled in the art will recognize that these molecules can be linked to one or more of any nucleotides comprising the nucleic acid molecule at several positions on the sugar, base or phosphate group.
  • oligonucleotides used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including Applied Biosystems. Any other means for such synthesis may also be employed; the actual synthesis of the oligonucleotides is well within the talents of one of ordinary skill in the art. It is also well known to use similar techniques to prepare other oligonucleotides such as the phosphorothioatcs and alkylated derivatives.
  • CPG modified amidites and controUed-pore glass
  • LNA monomers to enhance the potency, specificity and duration of action and broaden the routes of administration of oligonucleotides comprised of current chemistries such as OE, ANA, FANA, PS etc. This can be achieved by substituting some of the monomers in the current oligonucleotides by LNA monomers.
  • the LNA modified oligonucleotide may have a size similar to the parent compound or may be larger or preferably smaller.
  • LNA-modified oligonucleotides contain less than about 70%, more preferably less than about 60%, most preferably less than about 50% LNA monomers and that their sizes are between about 5 and 25 nucleotides, more preferably between about 12 and 20 nucleotides.
  • Preferred modified oligonucleotide backbones comprise, but not limited to, phosphorothioatcs, chiral phosphorothioatcs, phosphorodithioates, phosphotricstcrs, aminoalkylphosphotricstcrs, methyl and other alkyl phosphonatcs comprising 3'alkylcnc phosphonatcs and chiral phosphonatcs, phosphinatcs, phosphoramidatcs comprising 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2 -5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units arc linked 3'-5' to 5'- 3' or 2'-5' to 5'
  • Representative United States patents that teach the preparation of the above phosphorus containing linkages comprise, but are not limited to, US patent nos. 3,687,808; 4,469,863; 4,476,301 ; 5,023,243; 5, 177, 196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321 ,131 ; 5,399,676; 5,405,939; 5,453,496; 5,455, 233; 5,466,677; 5,476,925; 5,519, 126; 5,536,821 ; 5,541 ,306; 5,550, 1 1 1 ; 5,563, 253; 5,571 ,799; 5.587.361 ; and 5,625.050, each of which is herein incorporated by reference.
  • Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that arc formed by short chain alkyl or cycloalkyl intcmuclcosidc linkages, mixed hcteroatom and alkyl or cycloalkyl intcmuclcosidc linkages, or one or more short chain hcteroatomic or heterocyclic intcmuclcosidc linkages.
  • These comprise those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxanc backbones; sulfide, sulfoxide and sulfonc backbones; formacctyl and thioformacctyl backbones; methylene fonnacctyl and thioformacctyl backbones; alkene containing backbones; sulfamate backbones; mcthylcncimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and odiers having mixed N, 0, S and CH2 component pans.
  • siloxanc backbones siloxanc backbones
  • sulfide, sulfoxide and sulfonc backbones formacctyl and thioformacctyl backbones
  • Representative United States patents that teach the preparation of the above oligonucleosides comprise, but are not limited to, US patent nos. 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216, 141 ; 5,235,033; 5,264, 562; 5, 264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561 ,225; 5,596, 086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623, 070; 5,663,312; 5,633,360; 5,677.437; and 5,677.439, each of which is herein incorporated by reference.
  • both the sugar and the intemucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups.
  • the base units are maintained for hybridization with an appropriate nucleic acid target compound.
  • an oligonucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA).
  • PNA peptide nucleic acid
  • the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone.
  • nuclcobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone.
  • Representative United States patents that teach the preparation of PNA compounds comprise, but are not limited to, US patent nos. 5.539,082; 5,714,331 : and 5,719,262, each of which is herein incorporated by reference . Further teaching of PNA compounds can be found in Nielsen, et al. ( 1991) Science 254, 1497-1500.
  • the oligonucleotides with phosphorothioate backbones and oligonucleosides with hcteroatom backbones and in panicular- CH2-NH-0-CH2-,-CH2-N (CH3 0-CH2-known as a methylene (methylimino) or MMI backbone,- CH2-0-N (CH3)-CH2-,-CH2N(CH3)-N(CH3) CH2-and-0-N(CH3)- CH2-CH2- wherein the native phosphodicster backbone is represented as-0-P-0-CH2- of the above referenced US patent no. 5,489,677, and the amide backbones of the above referenced US patent no. 5,602,240. Also prcfcircd are oligonucleotides having morpholino backbone structures of the above-referenced US patent no. 5,034,506.
  • Modified oligonucleotides may also contain one or more substituted sugar moieties.
  • Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; 0-, S-, or N-alkyl; 0-, S-, or N-alkenyl; 0-, S- or N-alkynyl; or O alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C to CO alkyl or C2 to CO alkenyl and alkynyl.
  • n and m can be from 1 to about 10.
  • oligonucleotides comprise one of the following at the 2' position: C to CO, (lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH3, OCN, CI, Br, CN, CF3, OCF3, SOCH3, S02CH3, ON02, N02, N3, H2, hcterocyc!oalky], hetcrocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties.
  • a preferred modification comprises 2'-methoxyethoxy (2'-0-CH2CH20CH3, also known as 2'-0-(2- methoxyethyl) or 2'-M0E) i.e., an alkoxyalkoxy group.
  • a further preferred modification comprises 2'-dimethylaminooxycthoxy, i.e. , a 0(CH2)20N(CH3)2 group, also known as 2'-DMAOE, as described in examples herein below, and 2'- dimethylaminoethoxyethoxy (also known in the art as 2'O-dimethylaminoethoxyethyl or 2'- DMAEOE), i.e., 2'-0-CH2-0-CH2-N (CH2)2.
  • Oligonucleotides may also comprise nuclcobase (often referred to in the art simply as “base”) modifications or substitutions.
  • nuclcobase often referred to in the art simply as “base”
  • “unmodified” or “natural” nucleotides comprise the purine bases adenine (A) and guanine (G), and the pyrimidinc bases thymine (T), cytosine (C) and uracil (U).
  • Modified nucleotides comprise other synthetic and natural nucleotides such as 5-methylcytosinc (5-inc-C), 5-hydroxymcthyl cytosine, xanthine, hypoxanthinc, 2- aminoadeninc, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5- propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudo-uracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substitutcd adenines and guanines, 5-halo particularly 5-bromo, 5- trifluo
  • nucleotides comprise those disclosed in United States Patent No. 3,687,808, those disclosed in The Concise Encyclopedia of Polymer Science And Engineering', pages 858-859, Kroschwitz, J. I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., 'Angcwandle Chcmie, International Edition', 19 1 , 30, page 613, and those disclosed by Sanghvi, Y.S., Chapter 15, 'Antisense Research and Applications', pages 289-302, Crookc, S . and Lcblcu. B. ca., CRC Press, 1993.
  • nucleotides arc particularly useful for increasing the binding affinity of the oligomcric compounds of the invention.
  • These comprise 5-substitutcd pyrimidincs, 6- azapyrimidincs and N-2, N-6 and 0-6 substituted purines, comprising 2-aminopropyladeninc, 5- propynyluracil and 5-propynylcytosine.
  • 5- methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crookc, S.T.
  • Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates, which enhance the activity, cellular distribution, or cellular uptake of the oligonucleotide.
  • Such moieties comprise but are not limited to, lipid moieties such as a cholesterol moiety, cholic acid, a thioether, e.g., hexyl-S-tritylthiol, a thiocholesterol, an aliphatic chain, e.g., dodecandiol or undecyl residues, a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium l ,2-di-0-hexadecyl-rac-glycero-3-H-phosphonate, a polyamine or a polyethylene glycol chain, or Adamantane acetic acid, a palmityl moiety, or an octadccylamine or hcxylamino-carbonyl-t oxycholesterol moiety.
  • lipid moieties such as a cholesterol moiety, cholic acid, a thi
  • Representative United States patents that teach the preparation of such oligonucleotides conjugates comprise. but are not limited to, US patent nos. 4,828,979; 4,948,882; 5,218, 105; 5,525,465; 5,541 ,313; 5,545,730; 5,552, 538; 5,578,717, 5,580,731 ; 5,580,731 ; 5,591 ,584; 5,109,124; 5, 1 18,802; 5,138,045; 5,414,077; 5,486, 603; 5.512,439;
  • the compounds of the present invention can also be applied in the areas of drug discovery and target validation.
  • the present invention comprehends the use of the compounds and preferred target segments identified herein in drug discovery efforts to elucidate relationships that exist between BCL2-like 1 1 (BCL2L1 1 ) polynucleotides and a disease state, phenotype, or condition.
  • These methods include detecting or modulating BCL2L 1 1 polynucleotides comprising contacting a sample, tissue, cell, or organism with die compounds of the present invention, measuring the nucleic acid or protein level of BCL2L1 1 polynucleotides and or a related phenotypic or chemical endpoint at some time after treatment, and optionally comparing the measured value to a non-treated sample or sample treated with a further compound of the invention.
  • These methods can also be performed in parallel or in combination with other experiments to determine the function of unknown genes for the process of target validation or to determine the validity of a particular gene product as a target for treatment or prevention of a particular disease, condition, or phenotypc.
  • Transfer of an exogenous nucleic acid into a host cell or organism can be assessed by directly detecting the presence of the nucleic acid in the cell or organism. Such detection can be achieved by several methods well known in the art. For example, the presence of the exogenous nucleic acid can be detected by Southern blot or by a polymerase chain reaction (PGR) technique using primers that specifically amplify nucleotide sequences associated with the nucleic acid. Expression of the exogenous nucleic acids can also be measured using conventional methods including gene expression analysis. For instance, mRNA produced from an exogenous nucleic acid can be detected and quantified using a Northern blot and reverse transcription PCR (RT-PCR).
  • RT-PCR Northern blot and reverse transcription PCR
  • Expression of RN A from the exogenous nucleic acid can also be detected by measuring an enzymatic activity or a reporter protein activity.
  • antisense modulatory activity can be measured indirectly as a decrease or increase in target nucleic acid expression as an indication that the exogenous nucleic acid is producing the effector RNA.
  • primers can be designed and used to amplify coding regions of the target genes. Initially, the most highly expressed coding region from each gene can be used to build a model control gene, although any coding or non coding region can be used. Each control gene is assembled by inserting each coding region between a reporter coding region and its poly(A) signal.
  • These plasmids would produce an mRNA with a reporter gene in the upstream portion of the gene and a potential R Ai target in the 3' non-coding region.
  • the effectiveness of individual antisense oligonucleotides would be assayed by modulation of the reporter gene.
  • Reporter genes useful in the methods of the present invention include acetohydroxyacid synthase (AHAS), alkaline phosphatase (AP), beta galactosidase (LacZ), beta glucoronidase (GUS), chloramphenicol acetyltransferase (CAT), green fluorescent protein (GFP), red fluorescent protein (RFP), yellow fluorescent protein (YFP), cyan fluorescent protein (CFP), horseradish peroxidase (HRP), lucifcrasc (Luc), nopalinc synthase (NOS), octopinc synthase (OCS), and derivatives thereof.
  • AHAS acetohydroxyacid synthase
  • AP alkaline phosphatase
  • LacZ beta galactosidase
  • GUS beta glucoronidase
  • CAT chloramphenicol acetyltransferase
  • GFP green fluorescent protein
  • RFP red fluorescent protein
  • YFP yellow fluorescent protein
  • BCL2L 1 1 protein and mRNA expression can be assayed using methods known to those of skill in the art and described elsewhere herein. For example, immunoassays such as the EL1SA can be used to measure protein levels.
  • BCL2L 1 1 ELISA assay kits arc available commercially, e.g., from R&D Systems (Minneapolis, MN).
  • BCL2L1 1 expression e.g., mRNA or protein
  • a sample e.g.. cells or tissues in vivo or in vitro
  • an antisense oligonucleotide of the invention is evaluated by comparison with BCL2L1 1 expression in a control sample.
  • expression of the protein or nucleic acid can be compared using methods known to those of skill in the art with that in a mock-treated or untreated sample.
  • comparison with a sample treated with a control antisense oligonucleotide e.g., one having an altered or different sequence
  • a difference in the expression of the BCL2L1 1 protein or nucleic acid in a treated vs. an untreated sample can be compared with the difference in expression of a different nucleic acid (including any standard deemed appropriate by the researcher, e.g., a housekeeping gene) in a treated sample vs. an untreated sample.
  • a different nucleic acid including any standard deemed appropriate by the researcher, e.g., a housekeeping gene
  • the level of BCL2LI 1 mRNA or protein, in a sample treated with an antisense oligonucleotide of the present invention is increased or decreased by about 1.25-fold to about 10-fold or more relative to an untreated sample or a sample treated with a control nucleic acid.
  • the level of BCL2L1 1 mRNA or protein is increased or decreased by at least about 1.25-fold, at least about 1.3-fold, at least about
  • the compounds of the present invention can be utilized for diagnostics, therapeutics, and prophylaxis, and as research reagents and components of kits. Furthermore, antisense oligonucleotides, which are able to inhibit gene expression with 17, specificity, are often used by those of ordinary skill to elucidate the function of particular genes or to distinguish between functions of various members of a biological pathway.
  • the compounds of the present invention are useful as tools in differential and/or combinatorial analyses to elucidate expression patterns of a portion or the entire complement of genes expressed within cells and tissues.
  • biological system or “system” is defined as any organism, cell, cell culture or tissue that expresses, or is made competent to express products of the BCL2-like 1 1 (BCL2L 1 1) genes. These include, but arc not limited to, humans, transgenic animals, cells, cell cultures, tissues, xenografts, transplants and combinations thereof.
  • expression patterns within cells or tissues treated with one or more antisense compounds arc compared to control cells or tissues not treated with antisense compounds and the patterns produced arc analyzed for differential levels of gene expression as they pertain, for example, to disease association, signaling pathway, cellular localization, expression level, size, structure or function of the genes examined. These analyses can be performed on stimulated or unstimulated cells and in the presence or absence of other compounds that affect expression patterns.
  • Examples of methods of gene expression analysis known in the art include DNA arrays or microarrays, SAGE (serial analysis of gene expression), READS (restriction enzyme amplification of digested cDNAs), TOGA (total gene expression analysts), protein arrays and proteomics, expressed sequence tag (EST) sequencing, subtractive RNA fingerprinting (SuRF), subtractive cloning, differential display (DD), comparative genomic hybridization, FISH (fluorescent in situ hybridization) techniques and mass spectrometry methods.
  • the compounds of the invention arc useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding BCL2-like 11 (BCL2L1 1).
  • BCL2L1 1 BCL2-like 11
  • oligonucleotides that hybridize with such efficiency and under such conditions as disclosed herein as to be effective BCL2L1 1 modulators are effective primers or probes under conditions favoring gene amplification or detection, respectively.
  • These primers and probes are useful in methods requiring the specific detection of nucleic acid molecules encoding BCL2L1 1 and in the amplification of said nucleic acid molecules for detection or for use in further studies of BCL2L1 I .
  • Hybridization of the antisense oligonucleotides, particularly the primers and probes, of the invention with a nucleic acid encoding BCL2LI 1 can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabcling of the oligonucleotide, or any other suitable detection means. Kits using such detection means for detecting the level of BCL2L1 1 in a sample may also be prepared.
  • Antisense compounds have been employed as therapeutic moieties in the treatment of disease states in animals, including humans. Antisense oligonucleotide drugs have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that antisense . compounds can be useful therapeutic modalities that can be configured to be useful in treatment regimes for the treatment of cells, tissues and animals, especially humans.
  • an animal preferably a human, suspected of having a disease or disorder which can be treated by modulating the expression of BCL2L1 1 polynucleotides is treated by administering antisense compounds in accordance with this invention.
  • the methods comprise the step of administering to the animal in need of treatment, a therapeutically effective amount of BCL2L1 1 modulator.
  • the BCL2L1 1 modulators of the present invention effectively modulate the activity of the BCL2L1 1 or modulate the expression of the BCL2L 1 1 protein.
  • the activity or expression of BCL2L1 1 in an animal is inhibited by about 10% as compared to a control.
  • the activity or expression of BCL2L1 1 in an animal is inhibited by about 30%. More preferably, the activity or expression of BCL2L1 1 in an animal is inhibited by 50% or more.
  • the oligomcric compounds modulate expression of BCL2-likc 1 1 (BCL2L1 1 ) mRNA by at least 10%, by at least 50%, by at least 25%, by at least 30%, by at least 40%, by at least 50%, by at least 60%, by at least 70%, by at least 75%, by at least 80%, by at least 85%, by at least 90%, by at least 95%, by at least 98%, by at least 99%, or by 100% as compared to a control.
  • the activity or expression of BCL2-Iike 1 1 (BCL2LI I) and/or in an animal is increased by about 10% as compared to a control.
  • the activity or expression of BCL2L11 in an animal is increased by about 30% More preferably, the activity or expression of BCL2L1 1 in an animal is increased by 50% or more.
  • the oligomcric compounds modulate expression of BCL2L I 1 mRNA by at least 10%, by at least 50%, by at least 25%, by at least 30%, by at least 40%, by at least 50%, by at least 60%, by at least 70%, by at least 75%, by at least 80%, by at least 85%, by at least 90%, by at least 95%, by at least 98%, by at least 99%, or by 100% as compared to a control.
  • the reduction of the expression of BCL2-like 1 1 may be measured in serum, blood, adipose tissue, liver or any other body fluid, tissue or organ of the animal.
  • the cells contained within said fluids, tissues or organs being analyzed contain a nucleic acid molecule encoding BCL2L11 peptides and/or the BCL2L 1 1 protein itself.
  • the compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of a compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the compounds and methods of the invention may also be useful prophylactically.
  • Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide one or more moieties or conjugates that enhance the activity, cellular distribution or cellular uptake of the oligonucleotide.
  • moieties or conjugates can include conjugate groups covalently bound to functional groups such as primary or secondary hydroxyl groups.
  • Conjugate groups of the invention include intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethcrs, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers.
  • Typicalconjugatc groups include cholcstcrols, lipids, phospholipids, biotin, phenazinc, folate, phenanthridine, anthraquinone, acridinc, fluoresceins, rhodamines, coumarins, and dyes.
  • Groups that enhance the pharmacodynamic properties include groups that improve uptake, enhance resistance to degradation, and/or strengthen sequence- specific hybridization with the target nucleic acid.
  • Conjugate moieties include, but arc not limited to, lipid moieties such as a cholesterol moiety, cholic acid, a thiocthcr, e.g., hcxyl-5- rrityl thiol, a thiocholcstcrol, an aliphatic chain, e.g., dodecandiol or undccyl residues, a phospholipid, e.g., di-hcxadccyl-rac -glycerol or tricthylammonium l ,2-di-0-hcxadccyl-rac-glyccro-3-Hphosphonatc, a po!yaminc or a polyethylene glycol chain, or Adamantane acetic acid, a palmityl moiety, or an octadecylamine or hexylamino- carbonyl-oxycholcsterol moiety.
  • Oligonucleotides of the invention may also be conjugated to active drug substances, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, kctoprofen, (SM+ ⁇ pranoprofcn, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, flufenamic acid, folinic acid, a benzothiadiazidc, chlorothiazide, a diazepinc, indomcthicin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial or an antibiotic.
  • active drug substances for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fenbufen, kctoprofen, (SM+ ⁇ pranoprofcn, carprof
  • the compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as forcxample, liposomes, receptor-targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption.
  • invention practice involves administering at least one of the foregoing antisensc oligonucleotides with a suitable nucleic acid delivery system.
  • a suitable nucleic acid delivery system includes a non-viral vector opcrably linked to the polynucleotide. Examples of such nonviral vectors include the oligonucleotide alone (e.g. any one or more of SEQ ID NOS: 4 to 13) or in combination with a suitable protein, polysaccharide or lipid formulation.
  • suitable nucleic acid delivery systems include viral vector, typically sequence from at least one of an adenovirus, adenovirus-associated virus (AAV), helper-dependent adenovirus, retrovirus, or hemagglutinatin virus of Japan-liposome (HVJ) complex.
  • the viral vector comprises a strong eukaryotic promoter opcrably linked to the polynucleotide e.g., a cytomegalovirus (CM V) promoter.
  • CM V cytomegalovirus
  • Retroviral vectors include Moloney murine leukemia viruses and HIV-bascd viruses.
  • One preferred HIV-bascd viral vector comprises at least two vectors wherein the gag and pol genes are from an HIV genome and the env gene is from another virus.
  • DNA viral vectors are preferred.
  • These vectors include pox vectors such as orthopox or avipox vectors, herpesvirus vectors such as a herpes simplex 1 virus (HSV) vector, Adenovirus Vectors and Adeno-associated Virus Vectors.
  • HSV herpes simplex 1 virus
  • the antisensc compounds of the invention encompass any pharmaceutical ly acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof.
  • pharmaceutically acceptable salts refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesircd toxicological effects thereto.
  • pharmaceutically acceptable salts include oligonucleotides, preferred examples of pharmaceutically acceptable salts and their uses arc further described in U.S. Pat. No. 6,287,860, which is incorporated herein by reference.
  • the present invention also includes pharmaceutical compositions and formulations that include the antisensc compounds of the invention.
  • the pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer, intratracheal, intranasal, epidermal and transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration.
  • administration can be made by, e.g., injection or infusion into the cerebrospinal fluid.
  • Administration of antisensc RNA into cerebrospinal fluid is described, e.g., in U.S. Pat. App. Pub. No. 2007/01 17772, "Methods for slowing familial ALS disease progression," incorporated herein by reference in its entirety.
  • administration can be with one or more agents capable of promoting penetration of the subject antisense oligonucleotide across the blood-brain barrier.
  • Injection can be made, e.g., in the cntorhinal cortex or hippocampus. Delivery of neurotrophic factors by administration of an adenovirus vector to motor neurons in muscle tissue is described in, e.g., U.S. Pat. No. 6,632,427, "Adenoviral-vector-mediated gene transfer into medullary motor neurons,” incorporated herein by reference.
  • vectors directly to the brain e.g., the striatum, the thalamus, the hippocampus, or the substantia nigra
  • Delivery of vectors directly to the brain is known in the art and described, e.g., in U.S. Pat. No. 6,756,523, ''Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system particularly in brain, " incorporated herein by reference.
  • Administration can be rapid as by injection or made over a period of time as by slow infusion or administration of slow release formulations.
  • the subject antisense oligonucleotides can also be linked or conjugated with agents that provide desirable pharmaceutical or pharmacodynamic properties.
  • the antisense oligonucleotide can be coupled to any substance, known in the art to promote penetration or transport across the blood-brain barrier, such as an antibody to the transferrin receptor, and administered by intravenous injection.
  • the antisense compound can be linked with a viral vector, for example, that makes the antisense compound more effective and/or increases the transport of the antisense compound across the blood-brain barrier.
  • Osmotic blood brain barrier disruption can also be accomplished by, e.g., infusion of sugars including, but not limited to, meso erythritol, xylitol, D(+) galactose, D(+) lactose, D(+) xylose, dulcitol, myo-inositol, L(-) fructose, D(-) mannitol, D(+) glucose, D(+) arabinose, D(-) arabinose, cellobiose, D(+) maltose, D(+) raffmosc. L(+) rhamnose, D(+) melibiosc.
  • sugars including, but not limited to, meso erythritol, xylitol, D(+) galactose, D(+) lactose, D(+) xylose, dulcitol, myo-inositol, L(-) fruct
  • D(-) ribosc adonitol, D(+) arabitol, L(-) arabitol, D(+) fucose, U-) fucose, D ⁇ -) lyxosc, L(+) lyxose, and L(-) lyxosc, or amino acids including, but not limited to, glutaminc, lysine, argininc, asparaginc, aspaitic acid, cysteine, glutamic acid, glycine, histidinc, leucine, methionine, phenylalanine, proline, serine, threonine, tyrosine, valine, and taurine.
  • amino acids including, but not limited to, glutaminc, lysine, argininc, asparaginc, aspaitic acid, cysteine, glutamic acid, glycine, histidinc, leucine, methionine, phenyla
  • the subject antisense compounds may be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, for example, liposomes, receptor-targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption.
  • cationic lipids may be included in the formulation to facilitate oligonucleotide uptake.
  • L1POFECTIN available from GIBCO-BRL, Bethesda, MD.
  • Oligonucleotides with at least one 2'-0-mcthoxycthyl modification arc believed to be particularly useful for oral administration.
  • compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders.
  • Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
  • Coated condoms, gloves and the like may also be useful.
  • the pharmaceutical formulations of the present invention may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipicnt(s). In general, the formulations arc prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.
  • compositions of the present invention may be formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, gel capsules, liquid syrups, soft gels, suppositories, and enemas.
  • the compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media.
  • Aqueous suspensions may further contain substances that increase the viscosity of the suspension including, for example, sodium carboxymethylcellulosc, sorbitol and/or dextran.
  • the suspension may also contain stabilizers.
  • compositions of the present invention include, but are not limited to, solutions, emulsions, foams and liposome-containing formulations.
  • the pharmaceutical compositions and formulations of the present invention may comprise one or more penetration enhancers, carriers, excipients or other active or inactive ingredients.
  • Emulsions are typically heterogeneous systems of one liquid dispersed in another in the fonn of droplets usually exceeding 0.1 ⁇ in diameter. Emulsions may contain additional components in addition to the dispersed phases, and the active ding that may be present as a solution in cither the aqueous phase, oily phase or itself as a separate phase. Microcmulsions arc included as an embodiment of the present invention. Emulsions and their uses arc well known in the ait and arc further described in U.S. Pat. No. 6,287,860. ⁇
  • Formulations of the present invention include liposomal formulations.
  • liposome means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers. Liposomes are unilamellar or multilamellar vesicles which have a membrane formed from a lipophilic material and an aqueous interior that contains the composition to be delivered. Cationic liposomes arc positively charged liposomes that arc believed to interact with negatively charged DNA molecules to form a stable complex. Liposomes that arc pH-scnsitivc or negatively-charged arc believed to entrap DNA rather than complex with it. Both cationic and noncationic liposomes have been used to deliver DNA to cells.
  • Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids. When incorporated into liposomes, these specialized lipids result in liposomes with enhanced circulation lifetimes relative to liposomeslacking such specialized lipids.
  • stcrically stabilized liposomes arc those in which part of the vesicle-forming lipid portion of the liposome comprises one or more glycolipids or is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. Liposomes and their uses arc further described in U.S. Pat. No. 6,287,860.
  • compositions of the present invention may also include surfactants.
  • surfactants used in drug products, formulations and in emulsions is well known in the art. Surfactants and their uses are further described in U.S. Pat. No. 6,287,860, which is incorporated herein by reference.
  • the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides.
  • penetration enhancers also enhance the permeability of lipophilic drugs.
  • Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non- chclating nonsurfactants. Penetration enhancers and their uses arc further described in U S. Pat. No. 6,287,860, which is incorporated herein by reference.
  • formulations are routinely designed according to their intended use, i.e. route of administration.
  • Preferred formulations for topical administration include those in which the oligonucleotides of the invention are in admixture with a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants.
  • a topical delivery agent such as lipids, liposomes, fatty acids, fatty acid esters, steroids, chelating agents and surfactants.
  • Preferred lipids and liposomes include neutral (e.g. dioleoyl-phosphatidyl DOPE ethanolamine, dimyristoylphosphatidyl choline DMPC, distearolyphospharidyl choline) negative (e.g. dimyristoylphosphatidyl glycerol DMPG) and cationic (e.g. dioleoyltetramcthylaminopropyl DOTAP and dioleoyl-phosphatidyl cdianolaminc
  • oligonucleotides of the invention may be encapsulated within liposomes or may form complexes thereto, in particular to cationic liposomes.
  • oligonucleotides may be complexcd to lipids, in particular to cationic lipids.
  • Preferred fatty acids and esters, pharmaceutically acceptable salts thereof, and their uses arc further described in U.S. Pat. No. 6,287,860.
  • compositions and formulations for oral administration include powders or granules, microparticulatcs, nanoparticulates, suspensions or solutions in water or non-aqueous media, capsules, gel capsules, sachets, tablets or minitablcts. Thickeners, flavoring agents, diluents, cmulsificrs, dispersing aids or binders may be desirable.
  • Preferred oral formulations arc those in which oligonucleotides of the invention are administered in conjunction with one or more penetration enhancers surfactants and chelators.
  • Preferred surfactants include fatty acids and/or esters or salts thereof, bile acids and/or salts thereof.
  • Preferred bile acids/salts and fatty acids and their uses arc further described in U.S. Pat. No. 6,287,860, which is incorporated herein by reference.
  • a particularly preferred combination is the sodium salt of lauric acid, capric acid and UDCA.
  • Further penetration enhancers include polyoxyethylene-9-lauryl ether, polyoxycthylcnc-20-ccty] ether.
  • Oligonucleotides of the invention may be delivered orally, in granular form including sprayed dried particles, or complcxcd to form micro or nanoparticlcs. Oligonucleotide complcxing agents and their uses arc further described in U.S. Pat. No. 6,287.860, which is incorporated herein by reference.
  • compositions and formulations for parenteral, intrathecal or intraventricular administration may include sterile aqueous solutions that may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.
  • Certain embodiments of the invention provide pharmaceutical compositions containing one or more oligomeric compounds and one or more other chcmotherapcutic agents that function by a non-antisense mechanism.
  • chcmotherapcutic agents include but are not limited to cancer chemothcrapcutic drugs such as daunorubicin, daunomycin, dactinomycin, doxorubicin, epirubicin, idarubicin, esorubicin, bleomycin, mafosfamide, ifosfamidc, cytosine arabinosidc, bischloroethyl- nitrosurca, busulfan, mitomycin C, actinomycin D, mithramycin, prednisone, hydroxyprogesterone, testosterone, tamoxifen, dacarbazine, procarbazine, hexamcthylmclamine, pentamethylmelamine, mitoxantrone,
  • such chcmotherapcutic agents may be used individually (e.g., 5-FU and oligonucleotide), sequentially (e.g., 5-FU and oligonucleotide for a period of time followed by MTX and oligonucleotide), or in combination with one or more other such chcmotherapcutic agents (e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide).
  • individually e.g., 5-FU and oligonucleotide
  • sequentially e.g., 5-FU and oligonucleotide for a period of time followed by MTX and oligonucleotide
  • one or more other such chcmotherapcutic agents e.g., 5-FU, MTX and oligonucleotide, or 5-FU, radiotherapy and oligonucleotide.
  • Antiinflammatory drugs including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabinc, acyclovir and ganciclovir, may also be combined in compositions of the invention. Combinations of antisense compounds and other non-antisensc drugs arc also within the scope of this invention. Two or more combined compounds may be used together or sequentially.
  • compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted to a second nucleic acid target.
  • the first target may be a particular antisense sequence of BCL2-likc 1 1 (BCL2L 1 1 )
  • the second target may be a region from another nucleotide sequence.
  • compositions of the invention may contain two or more antisense compounds targeted to different regions of the same BCL2-Iike 1 1 (BCL2L 1 1) nucleic acid target.
  • antiscnsc compounds are illustrated herein and others may be selected from among suitable compounds known in the art. Two or more combined compounds may be used together or sequentially.
  • Dosing 100217
  • Dosing 100217
  • Dosing is believed to be within die skill of those in the art. Dosing is dependent on seventy and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the disease state is achieved.
  • Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC50s found to be effective in vitro and in vivo animal models.
  • dosage is from 0.01 ng to 100 g per kg of body weight, and may be given once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ⁇ g to 100 g per kg of body weight, once or more daily, to once every 20 years.
  • a patient is treated with a dosage of drug that is at least about 1 , at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 10, at least about 15, at least about 20. at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, or at least about 100 mg/kg body weight.
  • Certain injected dosages of antisense oligonucleotides are described, e.g., in U.S. Pat. No. 7,563,884, "Antisense modulation of PTPI B expression," incorporated herein by reference in its entirety.
  • Example I Design of antisense oligonucleotides specific for a nucleic acid molecule antisense to a BCL2-like II (HC 2L 11 ) and/or a sense strand of BCL2U I polynucleotide
  • oligonucleotide specific for or “oligonucleotide targets” refers to an oligonucleotide having a sequence (i) capable of forming a stable complex with a portion of the targeted gene, or (ii) capable of forming a stable duplex with a portion of an mRNA transcript of the targeted gene.
  • oligonucleotides are facilitated by using computer programs (e.g. IDT AntiSensc Design, IDT OligoAnalyzer) that automatically identify in each given sequence subsequences of 19-25 nucleotides that will form hybrids with a target polynucleotide sequence with a desired melting temperature (usually 50-60°C) and will not form sclf-dimers or other complex secondary structures.
  • computer programs e.g. IDT AntiSensc Design, IDT OligoAnalyzer
  • Selection of appropriate oligonucleotides is further facilitated by using computer programs that automatically align nucleic acid sequences and indicate regions of identity or homology. Such programs arc used to compare nucleic acid sequences obtained, for example, by searching databases such as GenBank or by sequencing PCR products. Comparison of nucleic acid sequences from a range of genes and intergenic regions of a given genome allows the selection of nucleic acid sequences that display an appropriate degree of specificity to the gene of interest. These procedures allow the selection of oligonucleotides that exhibit a high degree of complementarity to target nucleic acid sequences and a lower degree of complementarity to other nucleic acid sequences in a given genome. One skilled in the art will realize that there is considerable latitude in selecting appropriate regions of genes for use in the present invention.
  • An antisense compound is "specifically hybridizablc" when binding of the compound to the target nucleic acid interferes with the normal function of the target nucleic acid to cause a modulation of function and/or activity, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target nucleic acid sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and under conditions in which assays arc performed in the case of in vitro assays.
  • the hybridization properties of the oligonucleotides described herein can be determined by one or more in vitro assays as known in the art.
  • the propenies of the oligonucleotides described herein can be obtained by determination of binding strength between the target natural antisense and a potential drug molecules using melting curve assay.
  • the binding strength between the target natural antiscnsc and a potential drug molecule can be estimated using any of the established methods of measuring the strength of intcrmolccular interactions, for example, a melting curve assay.
  • Melting curve assay determines the temperature at which a rapid transition from double-stranded to singlc- stranded conformation occurs for the natural antiscnsc/ olcculc complex. This temperature is widely accepted as a reliable measure of the interaction strength between the two molecules.
  • a melting curve assay can be performed using a cDNA copy of the actual natural antisensc RNA molecule or a synthetic DNA or RNA nucleotide corresponding to the binding site of the Molecule.
  • Multiple kits containing all necessary reagents to perform this assay are available (e.g. Applied Biosystcms Inc. McltDoctor kit). These kits include a suitable buffer solution containing one of the double strand DNA (dsDNA) binding dyes (such as ABI HRM dyes, SYBR Green, SYTO, etc.).
  • dsDNA double strand DNA
  • the properties of the dsDNA dyes are such that they emit almost no fluorescence in free form, but arc highly fluorescent when bound to dsDNA.
  • the cDNA or a corresponding oligonucleotide are mixed with Molecule in concentrations defined by the particular manufacturer's protocols.
  • the mixture is heated to 95 °C to dissociate all preformed dsDNA complexes, then slowly cooled to room temperature or other lower temperature defined by the kit manufacturer to allow the DNA molecules to anneal.
  • the newly formed complexes are then slowly heated to 95 °C with simultaneous continuous collection of data on the amount of fluorescence that is produced by the reaction.
  • the fluorescence intensity is inversely proportional to the amounts of dsDNA present in the reaction.
  • the data can be collected using a real time PCR instrument compatible with the kit (e.g.ABl's StepOne Plus Real Time PCR System or lightTyper instrument, Roche Diagnostics, Lewes, UK).
  • Melting peaks are constructed by plotting the negative derivative of fluorescence with respect to temperature (-d(Fluorescence)/dT) on the y-axis) against temperature (x-axis) using appropriate software (for example lightTyper ( Roche) or SDS Dissociation Curve, ABI). The data is analyzed to identify the temperature of the rapid transition from dsDNA complex to single strand molecules. This temperature is called Tm and is directly proportional to the strength of interaction between the two molecules. Typically, Tm will exceed 40 °C.
  • Example 2 All antisense oligonucleotides used in Example 2 were designed as described in Example 1. The manufacturer (IDT Inc. of Coralville, 1A) was instructed to manufacture the designed phosphothioate bond oligonucleotides and provided the designed phosphothioate analogs shown in Table 1. The asterisk designation between nucleotides indicates the presence of phosphothioate bond.
  • the oligonucleotides required for the experiment in Example 2 can be synthesized using any appropriate state of the art method, for example the method used by IDT: on solid support, such as a 5 micron controlled pore glass bead (CPG), using phosphoramiditc monomers (normal nucleotides with all active groups protected with protection groups, e.g.
  • Protection groups prevent the unwanted reactions during oligonucleotide synthesis. Protection groups arc removed at the end of the synthesis process. The initial nucleotide is linked to the solid support through the .Vcarbon and the synthesis proceeds in the 3' to 5'dircction.
  • phosphorus is oxidized using iodine and water, if a phosphodiestcr bond is to be produced, or Beaucage reagent (3H- l ,2-benzodithiol-3-one-l , l- dioxidc), if a phosphothioatc bond is desired.
  • Beaucage reagent 3H- l ,2-benzodithiol-3-one-l , l- dioxidc
  • the oligonucleotide is cleaved from the solid support and dcprotcctcd using ammonium hydroxide at high temperature. Protection groups are washed away by desalting and the remaining oligonucleotides are lyophilized.
  • MCF-7 cells from ATCC (cat# HTB-22) were grown in growth media (MEM/EBSS (Hyclone cat #SH30024, or Mediatech cat # MT- 10-010-CV) + 10% FBS (Mediatech cat# MT35- 01 1 -CV)+ penicillin/streptomycin (Mediatech cat# MT30-002-CI)) at 37°C and 5% CCk
  • MEM/EBSS Hyclone cat #SH30024, or Mediatech cat # MT- 10-010-CV
  • FBS Mediatech cat# MT35- 01 1 -CV
  • penicillin/streptomycin Mediatech cat# MT30-002-CI
  • Oligonucleotides shipped by the manufacturer in lyophilized form were diluted to the concentration of 20 uM in deionized RNAsc/DNAse-free water. Two ⁇ of this solution was incubated with 400 ⁇ of OptiMEM media (Gibco cat#31 85-070) and 4 ⁇ of Lipofcctaminc 2000 (Invitrogen cat# 1 1668019) at room temperature for 20 min, then applied dropwisc to one well of the 6 well plate with MCF-7 cells. Similar mixture including 2 ⁇ of water instead of the oligonucleotide solution was used for the mock-transfcctcd controls.
  • the cDNA from this reverse transcription reaction was used to monitor gene expression by real time PCR using ABI Taqman Gene Expression Mix (cat#4369510) and primers probes designed by ABI (Applied Biosystems Taqman Gene Expression Assay: Hs00l 97982_ml by Applied Biosystems Inc., Foster City CA).
  • the following PCR cycle was used: 50°C for 2 min, 95°C for 10 min, 40 cycles of (95°C for 15 seconds, 60°C for 1 min) using StcpOnc Plus Real Time PCR Machine (Applied Biosystems). Fold change in gene expression after treatment with antiscnsc oligonucleotides was calculated based on the difference in 18S-normalized dCt values between treated and mock-transfcctcd samples.
  • Example 2 All antisense oligonucleotides used in Example 2 were designed as described in Example 1. The manufacturer (IDT Inc. of Coralville, 1A) was instructed to manufacture the designed phosphothioate bond oligonucleotides and provided the designed phosphothioate analogs shown in Table 1. The asterisk designation between nucleotides indicates the presence of phosphothioate bond.
  • the oligonucleotides required for the experiment in Example 2 can be synthesized using any appropriate state of the art method, for example the method used by IDT: on solid support, such as a 5 micron controlled pore glass bead (CPG), using phosphoramiditc monomers (normal nucleotides with all active groups protected with protection groups, e.g.
  • a chimeric backbone By alternating the two oxidizing agents, a chimeric backbone can be constructed.
  • the four step cycle described above is repeated for every nucleotide in the sequence.
  • the oligonucleotide is cleaved from the solid support and deprotectcd using ammonium hydroxide at high temperature. Protection groups are washed away by desalting and the remaining oligonucleotides are lyophilized.
  • HcpG2 cells from ATCC (cat# HB-8065) were grown in growth media (M EM/EBSS (Hyclonc cat #SH30024, or Mcdiatcch cat # MT-10-010-CV) +1.0% FBS (Mcdiatcch cat# MT35- 01 l -CV)+ penicillin/streptomycin (Mcdiatcch cat# MT30-O02-CI)) at 37°C and 5% C02.
  • M EM/EBSS Hyclonc cat #SH30024, or Mcdiatcch cat # MT-10-010-CV
  • Oligonucleotides shipped by the manufacturer in lyophilized form were diluted to the concentration of 20 uM in deionized RNAsc/DNAsc-frcc water. Two ⁇ of this solution was incubated with 400 ul of OptiMEM media (Gibco cat#31985-070) and 4 ⁇ of Lipofcctaminc 2000 (Invitrogcn cat# 1 1668019) at room temperature for 20 min, then applied dropwisc to one well of the 6 well plate with HcpG2 cells.
  • RNA 600 ng was added to the reverse transcription reaction performed using Verso cDNA kit from Thermo Scientific (cat#AB I453B) or High Capacity cDNA Reverse Transcription Kit (cat# 4368813) as described in the manufacturer's protocol.
  • the cDNA from this reverse transcription reaction was used to monitor gene expression by real time PGR using ABI Taqman Gene Expression Mix (cat#4369510) and primers probes designed by AB1 (Applied Biosystcms Taqman Gene Expression Assay: Hs00197982_ml (BCL2L1 1 ) by Applied Biosystems Inc., Foster City CA).
  • PCR cycle 50°C for 2 min, 95°C for 10 min, 40 cycles of (95°C for 15 seconds, 60°C for 1 min) using StepOne Plus Real Time PCR Machine (Applied Biosystems). Fold change in gene expression after treatment with antisense oligonucleotides was calculated based on the difference in 18S-normalized dCt values between treated and mock-transfected samples.
  • Oligonucleotides shipped by the manufacturer in lyophilized form were diluted to the concentration of 20 uM in deionized RNAsc/DNAsc-frcc water. Two ⁇ of this solution was incubated with 400 ⁇ ) of OptiMEM media (Gibco cat#31 85- 070) and 4 ⁇ of TransIT®-LTl Transfection Reagent (Minis cat # MIR 2300) at room temperature for 20 min, then applied dropwisc to one well of the 6 well plate with HcpG2 cells.
  • the cDNA from this reverse transcription reaction was used to monitor gene expression by real time PCR using ABI Taqman Gene Expression Mix (cat#4369510) and primers/probes designed by ABI (HsOOI97982_m l).
  • the following PCR cycle was used: 50°C for 2 min, 95°C for 10 min, 40 cycles of (95°C for 15 seconds, 60°C for 1 min) using StcpOnc Plus Real Time PCR Machine (Applied Biosystcms). Fold change in gene expression after treatment with antisense oligonucleotides was calculated based on the difference in 18S-normalized dCt values between treated and mock-transfected samples.
  • the level of apoptosis was detected in cells using the HT Titer TACS Assay kit following the manufacturer's protocol (Trcvigcn cat# 4822-96-K). Briefly, 48 hours post-oligonucleotide transfection cells were trypsinized, counted and replated in 96-well plates at a density of 100,000 cells/well. The 96-well plates were then incubated overnight at 37oC, 5% C02. The following morning the media was removed and the cells were fixed in 3.7% Buffered Formaldehyde Solution (Sigma-252549) rinsed with PBS and 100% methanol (Sigma-M 1775- 1 GA) and stored in 80% ethano! (Sigma-4935 1 1 ) at +4oC,
  • A549 cells (ATCC # CCL- 185TM) were transfected with 20nM CUR- 1 174, a p63 antisense oligonucleotide, and CUR- 1522, a BIM antisense oligonucleotide using LipofectamineTM 2000 Transfection Reagent (Invitrogcn).
  • Hep G2 cells (ATCC Cat# HB-8065) were transfected with CUR-1519, CUR- 1 21 and CUR-I522 at 20nM using LipofectamineTM 2000 Transfection Reagent (Invitrogcn). A subset of cells was also tranfectcd with 20nM CUR- 1505
  • Ashkcnazi A Targeting dcatli and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des oligonucléotides anti-sens qui modulent l'expression et/ou la fonction de la protéine 11 de type BCL2 (BCL2L11), en particulier, par le ciblage de polynucléotides anti-sens naturels de la protéine 11 de type BCL2 (BCL2L11). L'invention concerne également l'identification de ces oligonucléotides anti-sens et leur utilisation dans le traitement de maladies et de troubles associés à l'expression de BCL2L11.
PCT/US2011/037079 2010-05-19 2011-05-19 Traitement de maladies liées à la protéine 11 de type bcl2 (bcl2l11) par inhibition de transcrits anti-sens naturels de bcl2l11 Ceased WO2011146674A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34625210P 2010-05-19 2010-05-19
US61/346,252 2010-05-19

Publications (2)

Publication Number Publication Date
WO2011146674A2 true WO2011146674A2 (fr) 2011-11-24
WO2011146674A3 WO2011146674A3 (fr) 2012-04-05

Family

ID=44992328

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/037079 Ceased WO2011146674A2 (fr) 2010-05-19 2011-05-19 Traitement de maladies liées à la protéine 11 de type bcl2 (bcl2l11) par inhibition de transcrits anti-sens naturels de bcl2l11

Country Status (3)

Country Link
AR (1) AR081209A1 (fr)
TW (1) TW201201819A (fr)
WO (1) WO2011146674A2 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9328346B2 (en) 2010-11-12 2016-05-03 The General Hospital Corporation Polycomb-associated non-coding RNAs
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
US10059941B2 (en) 2012-05-16 2018-08-28 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
US10058623B2 (en) 2012-05-16 2018-08-28 Translate Bio Ma, Inc. Compositions and methods for modulating UTRN expression
US10174315B2 (en) 2012-05-16 2019-01-08 The General Hospital Corporation Compositions and methods for modulating hemoglobin gene family expression
US10174323B2 (en) 2012-05-16 2019-01-08 The General Hospital Corporation Compositions and methods for modulating ATP2A2 expression
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
EP3511416A1 (fr) 2012-05-16 2019-07-17 Translate Bio MA, Inc. Composés et procédés pour moduler l'expression génique
WO2020007702A1 (fr) 2018-07-02 2020-01-09 Roche Innovation Center Copenhagen A/S Oligonucléotides antisens ciblant bcl2l11
US10655128B2 (en) 2012-05-16 2020-05-19 Translate Bio Ma, Inc. Compositions and methods for modulating MECP2 expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
US10858650B2 (en) 2014-10-30 2020-12-08 The General Hospital Corporation Methods for modulating ATRX-dependent gene repression
US10900036B2 (en) 2015-03-17 2021-01-26 The General Hospital Corporation RNA interactome of polycomb repressive complex 1 (PRC1)
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
US12319913B2 (en) 2018-10-31 2025-06-03 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A1VAREZ-GARCIA, I. ET AL.: 'MicroRNA functions in animal development and human disease.' DEVELOPMENT. vol. 132, no. 21, November 2005, pages 4653 - 62 *
CLOONAN, N. ET AL.: 'The miR-17-5p microRNA is a key regulator of the Gl/S phase cell cycle transition.' GENOME BIOLOGY. vol. 9, no. 8, 2008, page R127 *
LU, Y. ET AL.: 'A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference.' NUCLEIC ACIDS RESEARCH vol. 37, no. 3, February 2009, page E24 *
MEISTER, G. ET AL.: 'Mechanisms of gene silencing by double-stranded RNA.' NATURE. vol. 431, no. 7006, 16 September 2004, pages 343 - 9 *
STENVANG, J. ET AL.: 'MicroRNAs as targets for antisense-based therapeutics.' EXPERT OPINION ON BIOLOGICAL THERAPY. vol. 8, no. 1, January 2008, pages 59 - 81 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10358644B2 (en) 2010-11-12 2019-07-23 The General Hospital Corporation Polycomb-associated non-coding RNAs
US9816094B2 (en) 2010-11-12 2017-11-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
US9856479B2 (en) 2010-11-12 2018-01-02 The General Hospital Corporation Polycomb-associated non-coding RNAs
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
US10053694B2 (en) 2010-11-12 2018-08-21 The General Hospital Corporation Polycomb-associated non-coding RNAS
US11066673B2 (en) 2010-11-12 2021-07-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
US9328346B2 (en) 2010-11-12 2016-05-03 The General Hospital Corporation Polycomb-associated non-coding RNAs
US10119144B2 (en) 2010-11-12 2018-11-06 The General Hospital Corporation Polycomb-associated non-coding RNAs
US10058623B2 (en) 2012-05-16 2018-08-28 Translate Bio Ma, Inc. Compositions and methods for modulating UTRN expression
US10655128B2 (en) 2012-05-16 2020-05-19 Translate Bio Ma, Inc. Compositions and methods for modulating MECP2 expression
US11788089B2 (en) 2012-05-16 2023-10-17 The General Hospital Corporation Compositions and methods for modulating MECP2 expression
EP3511416A1 (fr) 2012-05-16 2019-07-17 Translate Bio MA, Inc. Composés et procédés pour moduler l'expression génique
US10174315B2 (en) 2012-05-16 2019-01-08 The General Hospital Corporation Compositions and methods for modulating hemoglobin gene family expression
US10059941B2 (en) 2012-05-16 2018-08-28 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
US10174323B2 (en) 2012-05-16 2019-01-08 The General Hospital Corporation Compositions and methods for modulating ATP2A2 expression
US10858650B2 (en) 2014-10-30 2020-12-08 The General Hospital Corporation Methods for modulating ATRX-dependent gene repression
US10426788B2 (en) 2015-03-13 2019-10-01 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
US10900036B2 (en) 2015-03-17 2021-01-26 The General Hospital Corporation RNA interactome of polycomb repressive complex 1 (PRC1)
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
US12371693B2 (en) 2016-11-01 2025-07-29 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
WO2020007702A1 (fr) 2018-07-02 2020-01-09 Roche Innovation Center Copenhagen A/S Oligonucléotides antisens ciblant bcl2l11
US12319913B2 (en) 2018-10-31 2025-06-03 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer

Also Published As

Publication number Publication date
AR081209A1 (es) 2012-07-04
TW201201819A (en) 2012-01-16
WO2011146674A3 (fr) 2012-04-05

Similar Documents

Publication Publication Date Title
US9970008B2 (en) Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
US10100315B2 (en) Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4
EP2593547B1 (fr) Traitement de maladies liées à « discs large homolog » (dlg) par inhibition de transcrit antisens naturel de dlg
EP2633052B1 (fr) Traitement de maladies associées au régulateur du développement lié à l'interféron 1 (ifrd1), par l'inhibition du produit de la transcription antisens naturel de l'ifrd1
EP2519632B1 (fr) Traitement de maladies liées au substrat 2 du récepteur de l'insuline (irs2) par inhibition du produit de transcription antisens naturel d'irs2 et du facteur de transcription e3 (tfe3)
WO2011146674A2 (fr) Traitement de maladies liées à la protéine 11 de type bcl2 (bcl2l11) par inhibition de transcrits anti-sens naturels de bcl2l11
CA2785173A1 (fr) Traitement de maladies liees au facteur respiratoire nucleaire 1 (nrf1) par l'inhibition du produit de transcription antisens naturel de nrf1
EP2718439A1 (fr) Traitement des maladies associées à la frataxine (fxn) par inhibition de la transcription de l'anti-sens naturel de la fxn
WO2011146675A2 (fr) Traitement de maladies liées à la protéine 2 de l'homéoboîte lim (lhx2) par inhibition de transcrits anti-sens naturels de lhx2
WO2012009347A2 (fr) Traitement des maladies liées au composant 3 se liant à bcl2 (bbc3) par inhibition du transcrit antisens naturel anti-bbc3
WO2011038205A2 (fr) Traitement de maladies liées à l'hormone de croissance (hc) par inhibition du produit de la transcription antisens naturel de l'hormone de croissance (hc)
HK1250742B (en) Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
HK1178564B (en) Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
HK1178564A (en) Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
HK1172367B (en) Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
HK1172367A (en) Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
HK1180366B (en) Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
HK1180366A (en) Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
HK1179300A (en) Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
HK1179300B (en) Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
HK1185375A (en) Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1
HK1185375B (en) Treatment of interferon-related developmental regulator 1 (ifrd1) related diseases by inhibition of natural antisense transcript to ifrd1
HK1172368B (en) Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
HK1172368A (en) Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11784213

Country of ref document: EP

Kind code of ref document: A2